

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
30 September 2004 (30.09.2004)

PCT

(10) International Publication Number
WO 2004/083430 A2

(51) International Patent Classification⁷: **C12N 15/11**,
C07H 21/04, A61K 31/713, A61P 35/00

(74) Agent: **PLOUGMANN & VINGTOFT A/S**, Sundkrogs-
gade 9, P.O. Box 831, DK-2100 Copenhagen Ø (DK).

(21) International Application Number:
PCT/DK2004/000192

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(22) International Filing Date: 22 March 2004 (22.03.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PA 2003 00442 21 March 2003 (21.03.2003) DK
60/456,888 21 March 2003 (21.03.2003) US
PA 2003 01625 31 October 2003 (31.10.2003) DK
PA 2004 00145 30 January 2004 (30.01.2004) DK

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Euro-
pean (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,
GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **SAN-
TARIS PHARMA A/S** [DK/DK]; Bøge Allé 3, DK-2970
Hørsholm (DK).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **ELMÉN, Joacim**
[SE/SE]; Olof af Acrelsväg 3, 6tr, SE-171 64 Solna (SE).
WAHLESTEDT, Claes [SE/SE]; Strandvägen 29, SE-114
56 Stockholm (SE). **LIANG, Zicai** [SE/SE]; Sevensvägen
4, SE-174 46 Sundbyberg (SE). **SØRENSEN, Anders,**
Malling [DK/DK]; Gråstengade 3, 1. tv., DK-1677
København V (DK). **ØRUM, Henrik** [DK/DK]; Vil-
drosevej 3, DK-3500 Værløse (DK). **KOCH, Troels**
[DK/DK]; Funkiavej 47, DK-2300 Copenhagen S (DK).

Published:

— *without international search report and to be republished
upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: **SHORT INTERFERING RNA (siRNA) ANALOGUES**

(57) Abstract: The present invention is directed to novel double-stranded short interfering (siRNA) analogues comprising locked nucleic acid (LNA) monomers. Such compounds induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). The compounds disclosed herein has improved properties compared to non-modified siRNAs and may, accordingly, be useful as therapeutic agents, e.g., in the treatment of various cancer forms. More particularly, the present invention is directed to siRNA analogues comprising a sense strand and an antisense strand, wherein each strand comprises 12-35 nucleotides and wherein the siRNA analogues comprise at least one locked nucleic acid (LNA) monomer.



WO 2004/083430 A2

SHORT INTERFERING RNA (siRNA) ANALOGUES

FIELD OF THE INVENTION

The present invention is directed to novel double-stranded short interfering (siRNA) analogues comprising locked nucleic acid (LNA) monomers. Such compounds induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). The compounds disclosed herein has improved properties compared to non-modified siRNAs and may, accordingly, prove useful as therapeutic agents, e.g., in the treatment of various cancer forms.

BACKGROUND OF THE INVENTION

Discovery of RNA interference (RNAi) in *C. Elegans* was made by Fire et al. (Nature, 1998, 391, 806-811). Long stretches of double stranded RNA (dsRNA) was found to have a potent knock-down effect on gene expression that could last for generations in the worm.

RNA interference (RNAi) rapidly became a functional genomic tool in *C. Elegans* (early RNA interference is reviewed by Fire (TIG, 1999, 15, 358-363) and Bosher and Labouesse (Nature Cell Biology, 2000, 2, E31-E36)). The first studies where RNA interference was demonstrated to work in vertebrates were performed in zebrafish embryos and mouse oocytes (Wargelius et al., Biochem. Biophys. Res. Com. 1999, 263, 156-161, Wianny and Zernicka-Goetz, Nature Cell Biology, 2000, 2, 70-75). Since dsRNA induces non-specific effects in mammalian cells it has been argued that these mechanisms were not fully developed in the mouse embryonic system (Alexopoulou et al., Nature, 2001, 413, 732-738, Reviews: Stark et al., Annu. Rev. Biochem., 1998, 67, 227-264 and Samuel, Clin. Micro. Rev., 2001, 14, 778-809).

As far as *C. Elegans* and *Drosophila* are concerned, it has been shown that the long RNAi strands are degraded to short double strands (21-23 nucleotides) and that these degraded forms mediated the interference (Zamore et al., Cell, 2000, 101, 25-33 and Elbashir et al., Gen. Dev., 2001, 15, 188-200). Elbashir et al. (Gen. Dev., 2001, 15, 188-200) showed that a sense or antisense target is cleaved equally and that both strands in siRNA can guide cleavage to target antisense or sense RNA, respectively. It was unambiguously shown by Elbashir et al. (Nature, 2001, 411, 494-498) that the siRNAs mediate potent knock-down in a variety of mammalian cell lines and probably escaped the adverse non-specific effects of long dsRNA in mammalian cells. This discovery was a hallmark in modern biology and the application of siRNAs as therapeutics soon became an attractive field of research (Reviewed by McManus and Sharp, Nature Reviews Genetics, 2002, 3, 737-747 and Thompson, DDT, 2002, 7, 912-917).

DsRNAs are rather stable in biological media. However, the moment the duplex is dissociated into the individual strands these are, by virtue of being RNA, immediately degraded. One of the strategies to bring further stability to siRNA has been to introduce chemically modified RNA residues into the individual strands of the siRNA. It is well known
5 that synthetic RNA analogues are much more stable in biological media, and that the increased stability is also induced to the proximate native RNA residues. By greater stability is mainly meant increased nuclease resistance but also better cellular uptake and tissue distribution may be conferred by such modifications. Several siRNA analogues have been described:

10

Pre-siRNA (Parrish et al. Mol. Cell, 2000, 6, 1077-1087) show tolerance for certain backbone modifications for RNAi in *C. elegans*. By *in vitro* transcription of the two different strands in presence of modified nucleotides, it was possible to show that phosphorothioates are tolerated in both the sense and antisense strand and so are 2'-fluorouracil
15 instead of uracil. 2'-Aminouracil and 2'-aminocytidine reduce the RNAi activity when incorporated into the sense strand and the activity is completely abolished when incorporated in the antisense strand. With an exchange of uracil to 2'-deoxythymidine in the sense strand the effect is also reduced, and even more when the exchange is in the antisense strand. If one or both strand(s) consist entirely of DNA monomers, the RNAi
20 activity is abolished. In the above-mentioned study, base modifications were also investigated; It was found that 4-thiouracil and 5-bromouracil are tolerated in both stands, whereas 5-iodouracil and 5-(3-aminoallyl)uracil reduce the effect in the sense strand and even more in the antisense strand. Replacing guanosine with inosine markedly reduces the activity, independtly of whether the modification is performed in the sense or antisense
25 strand.

30

However, UU 3' overhangs can be exchanged with 2'-deoxythymidine 3' overhangs and are well tolerated (Elbashir et al., Nature, 2001, 411, 494-498 and Boutla et al., Curr. Biol., 2001, 11, 1776-1780).

It has also been shown that DNA monomers can be incorporated in the sense strand without compromising the activity.

Elbashir et al., EMBO, 2001, 20, 6877-6888) showed that modified siRNA containing four
35 deoxynucleotides in each 3'-end of the siRNA maintained full activity. Furthermore, it was found that the activity was abolished if the siRNA contained only one base-pair mismatch in the "middle" of the molecule.

However, it has also been reported that 1-2 mismatches can be tolerated as long as the mismatches are introduced in the sense strand (Holen et al., NAR, 2002, 30, 1757-1766; Hohjoh, FEBS Lett., 2002, 26179, 1-5; Hamada et al., Antisense and Nucl. Acid Drug Dev., 2002, 12, 301-309; and Boutla et al., Curr. Biol., 2001, 11, 1776-1780)).

5

Nykänen et al. (Cell, 2001, 107, 309-321) showed the need for ATP in making siRNA out of RNAi, but also in the later steps to exert the siRNA activity. ATP is needed for unwinding and maintaining a 5'-phosphate for RISC recognition. The 5'-phosphate is necessary for siRNA activity. Martinez et al. (Cell, 2002, 110, 563-574) showed that a single strand can
10 reconstitute the RNA-induced silencing complex (RISC, Hammond et al., Nature, 2000, 404, 293-296) and that a single antisense strand has activity especially when 5'-phosphorylated. 5'-antisense strand modification inhibits activity while both the 3' end and the 5' end of the sense strand can be modified.

15 Amarzguioui et al. (NAR, 2003, 31, 589-595) confirmed the above-mentioned findings, and it was concluded that a mismatch is tolerated as long as it is not too close to the 5' end of the antisense strand. A mismatch 3-5 nucleotides from the 5' end of the antisense strand markedly diminishes the activity. However, it was shown that two mismatches are tolerated if they are in the "middle" or towards the 3' end of the antisense strand, though
20 with a slightly reduced activity.

Modifications, such as phosphorothioates and 2'-O-methyl RNA, have been introduced at the termini of siRNA (Amarzguioui et al., NAR, 2003, 31, 589-595) and they were well tolerated. 2'-O-allylation reduces the effect when present in the 5' end of the antisense
25 strand

The bi-cyclic nucleoside analogue ENA (2'-O,4'-C-ethylene thymidine (ENA thymidine, eT) has also been incorporated into siRNA (Hamada et al., Antisense and Nucl. Acid Drug Dev., 2002, 12, 301-309). It was shown that two ENA thymidines in the 5' end of the sense
30 strand deteriorated the effect. It was concluded by Hamada *et al.* (2002) that: "using 2'-O,4'-C-ethylene thymidine, which is a component of ethylene-bridged nucleic acids (ENA), completely abolished RNAi".

More recently, a number of siRNAs containing incorporated LNA monomers were described
35 by Braasch et al. (Biochemistry 2003, 42, 7967-7975).

In conclusion, it has been shown that the antisense strand is more sensitive to modifications than is the sense strand. Without being limited to any specific theory, this phenomena is, at least partly, believed to be based on the fact that the structure of the

antisense/target duplex has to be native A-form RNA. The sense strand of siRNA can be regarded as a "vehicle" for the delivery of the antisense strand to the target and the sense strand is not participating in the enzyme-catalysed degradation of RNA. Thus, in contrast to the antisense strand, modifications in the sense strand is tolerated within a certain window even though the modifications induce changes to the A-form structure of the siRNA. If changes are introduced in the antisense strand they have to be structurally balanced within the recognition frame of the native RNA induced silencing complex (RISC).

Evidently, there is a need in the field for novel and improved siRNA analogues which possess potent *in vivo* properties, an increased biostability (corresponding to an increased T_m), an increased nuclease resistance, improved cellular uptake and/or improved tissue distribution as compared to the siRNA compounds which are presently available.

Thus, the object of the present invention is to provide improved siRNA analogues having one or more of the above-mentioned improved properties. The present invention thus provides improved siRNA analogues which, *inter alia*, show a high degree of biostability and/or nuclease stability and which efficiently targets RNA, such as mRNA or pre-mRNA, or a variety of structural RNAs such as tRNA, snRNA, scRNA, rRNA or even regulatory RNAs like microRNAs

20

BRIEF DESCRIPTION OF THE INVENTION

Accordingly, in a first aspect the present invention relates to a double-stranded compound comprising a sense strand and an antisense strand, wherein each strand comprises 12-35 nucleotides and wherein said compound comprises at least one locked nucleic acid (LNA) monomer.

25

In another aspect the present invention relates to a pharmaceutical composition comprising a compound according to the invention and a pharmaceutically acceptable diluent, carrier or adjuvant.

30

In a further aspect the present invention relates to a compound according to the invention for use as a medicament.

In a still further aspect the present invention relates to the use of a compound according to the invention for the manufacture of a medicament for the treatment of cancer or Severe Acute Respiratory Syndrome (SARS).

35

In an even further aspect the present invention relates to a method for treating cancer or Severe Acute Respiratory Syndrome (SARS), said method comprising administering a

compound according to the invention or a pharmaceutical composition according to the invention to a patient in need thereof.

Other aspects of the present invention will be apparent from the below description and the
5 appended claims.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the two furanose conformations (S-type and N-type).

10 FIG 2 shows the improved stability of siLNA over siRNA in biological fluids. GL3+/- is rapidly degraded while slightly modified siLNA (No. 2185/2186) and more heavily modified siLNA (No. 2703-01/2186) exhibit a markedly improved stability. The stability study was performed in 10% foetal bovine serum in physiological salt solution at 37°C.

15 FIG. 3 shows the down-regulation of the endogenous NPY gene in PC12 cells by siLNAs. The tested compounds were (from left to right): 2nd bar: unrelated siRNA; 3rd bar: NPY+/1, 4th bar: 2796/NPY-; 5th bar: 2795/NPY+; 6th bar: NPY+/2797; 7th bar: 2796/2797.

20 FIG. 4 shows the effect of siLNA in targeting firefly luciferase and modulation of the expression. The left lines represent the sense strand and the right lines represent the antisense strand of the siLNA. The marks on the individual lines represent the position of the LNA monomers. The last two lines on the right represent control siRNA. The first bar (on the left) represents full, non-modulated, luciferase reporter expression to which all
25 samples are normalised. The tested compounds were (from left to right): 2nd bar: GL3+/-; 3rd bar: GL3+/2186; 4th bar: GL3+/2187; 5th bar: 2184/GL3-; 6th bar: 2184/2186; 7th bar: 2184/2187; 8th bar: 2185/GL3-; 9th bar: 2185/2186; 10th bar: 2185/2187; 11th bar: 2703-1/GL3-; 12th bar: 2703-1/2186; 13th bar: GL3+/2189; 14th bar: unrelated siRNA.

30

FIG. 5 shows the effect of siLNA in targeting *Renilla* luciferase and modulation of the expression. The left lines represent the sense strand and the right lines represent the antisense strand of the siLNA. The marks on the individual lines represent the position of the LNA monomers. The first bar represents full, non-modulated luciferase reporter
35 expression, to which all samples are normalised. The tested compounds were (from left to right): 2nd bar: RL+/-; 3rd bar: RL+/2699-1; 4th bar: 2700-1/2699-1; 5th bar: 2702-1/2699-1; 6th bar: RL+/2701-1; 7th bar: 2700-1/2701-1; 8th bar: 2702-1/2701-1.

FIG. 6 shows the stability in rat serum of single-stranded oligos containing LNA and RNA monomers, double-stranded (ds) RNA and single-stranded (ss) RNA. dsRNA and ssRNA were degraded immediately while intact single-stranded oligos containing LNA and RNA monomers could be detected after 20-40 minutes. The tested oligos were 2189 and the
5 corresponding ssRNA (GL3-) and dsRNA (GL3+/1).

FIG. 7 shows siLNA and siRNA compounds for targeting SARS. Capital letters: Beta-D-oxy LNA monomer. Small letters: RNA monomer.

10 FIG. 8 shows the cytopathic effect (CPE) in vero cells when infected with SARS and the reduced CPE after siRNA treatment. Shown is siRNA SARS 1. Mock is treated with the transfectionagent lipofectamine 2000 alone. Also shown is non-infected cells.

FIG. 9 shows inhibition of SARS-induced cytotoxicity by siRNA and siLNA. The tested
15 compounds were: SARS 1: 2842-1/2843-1; SARS 2: 2872-1/2845-1; SARS 3: 2846-1/2847-1; SARS 4: 2848-1/2849-1 as well as the corresponding unmodified siRNAs. No difference in the treatment with siLNA and siRNA could be detected for the most efficient site, SARS 1. The medium efficient site, SARS 3, was improved by siLNA to be as efficient as the SARS 1 site. The two sites that did not shown siRNA efficiency at all, SARS 2 and
20 SARS 4, did not show any effect by siLNA treatment either. The inhibitory effect is reduced at high viral doses (60,000 TCID₅₀). Controls were luciferase (Luc) and neuropeptide Y (NPY) siRNA and siLNA. No adverse effects were seen by the siLNA controls. Cytotoxicity was measured as lactate dehydrogenase (LDH) release at 50 hours post infection. The different graphs represent different viral doses (tissue culture infectious dose 50, TCID₅₀).
25

FIG. 10 shows the proposed mechanism of RISC loading where the helicase is unwinding the siRNA duplex at the weakest binding end.

FIG. 11 shows the effect of single base-pair mismatches incorporated opposite to the 5'
30 end of the antisense strand. Lines are RNA, circles indicate LNA monomers and crosses illustrate mismatch incorporations. The tested compounds were (from left to right): Renilla luciferase: 2nd bar: RL+/-; 3rd bar: RL+/2701-1; 4th bar: RL+(pos. 19A→C)/2701-1; 5th bar: RL+(pos. 19A→C)/-; Firefly luciferase: 2nd bar: GL3+/-; 3rd bar: GL3+/2187; 4th bar: GL3+(pos. 19A→C)/2187; 5th bar: GL3+(pos. 19A→C)/-.

35 FIG. 12 shows the effect of LNA monomer position in the antisense strand. Lines are RNA, circles indicate LNA monomers. The tested compounds were (from left to right): 2nd bar: GL3+/-; 3rd bar: GL3+/2187; 4th bar: GL3+/2789; 5th bar: GL3+/2790; 6th bar:

GL3+/2792; 7th bar: GL3+/2793; 8th bar: GL3+/2794; 9th bar: GL3+/2864; 10th bar: GL3+/2865; 11th bar: GL3+/2866; 12th bar: GL3+/2867.

FIG. 13 shows the siLNA improvement of medium-efficient target sites. MOCK represents
5 no oligo. Ren1 is the optimal target site for siRNA and Ren2 and Ren3 are less potent sites. Lines are RNA and circles indicate LNA monomers. The tested compounds were: Ren1: RL+/-; Ren2: 2863/corresponding unmodified antisense strand; Ren3: 2826/corresponding unmodified antisense strand, as well as the corresponding unmodified siRNAs.

10 FIG. 14 shows the concentration-depending gene silencing effect of siLNA and siRNA.

FIG. 15 shows improved designs of modified siRNAs by incorporation of DNA and LNA monomers.

15 FIG. 16 shows the decreased siLNA efficacy by using a LNA monomer with a bulky nucleobase (T instead of U) at cleaving position 10 in the antisense strand. The tested compounds were: siRNA: GL3+/-; siLNA10T: GL3+/2865; siLNA10U: GL3+/2865-U.

FIG. 17 shows the inhibition of SARS sense/antisense target in 3'-UTR of firefly luciferase
20

FIG. 18 shows the *in vivo* anti-tumour effect of two anti-EGFP siLNAs (3029/3031 and 3030/3031) on 15PC3-EGFP xenograft NMRI mice.

FIG. 19 shows the tumour volume of siLNA- and-saline treated 15PC3-EGFP xenograft
25 NMRI mice using Alzet 1007D minipumps. The tumours were implemented at day 0. The treatment was initiated on day 7 and terminated on day 12. As can be seen, the siLNA-treated mice had a tumour size corresponding to the control mice.

FIG. 20 shows that siLNA duplexes are intact after 7 day in Alzet 1007D minipumps.
30

DETAILED DESCRIPTION OF THE INVENTION

Definitions

In the present context the term "nucleotide" means a 2-deoxyribose (DNA) unit or a ribose
35 (RNA) unit which is bonded through its number one carbon to a nitrogenous base, such as adenine (A), cytosine (C), thymine (T), guanine (G) or uracil (U), and which is bonded through its number five carbon atom to an internucleoside linkage group (as defined below) or to a terminal groups (as defined below). Accordingly, when used herein the term "nucleotide" encompasses RNA units (or monomers) comprising a ribose unit which is

bonded through its number one carbon to a nitrogenous base, such as A, C, T, G or U, and which is bonded through its number five carbon atom to a phosphate group or to a terminal group. Analogously, the term "nucleotide" also encompasses DNA units (or monomers) comprising a 2-deoxyribose unit which is bonded through its number one carbon to a nitrogenous base, such as A, C, T, G or U, and which is bonded through its number five carbon atom to a phosphate group or to a terminal group. The term "nucleotide" also covers variants or analogues of such RNA and DNA monomers. A detailed disclosure of such RNA and DNA monomer variants or analogues are given below.


In the present context the term "nucleoside" means a 2-deoxyribose (DNA) unit or a ribose (RNA) unit which is bonded through its number one carbon to a nitrogenous base, such as adenine (A), cytosine (C), thymine (T), guanine (G) or uracil (U). Accordingly, when used herein the term "nucleoside" encompasses RNA units (or monomers) comprising a ribose unit which is bonded through its number one carbon to a nitrogenous base, such as A, C, T, G or U. Analogously, the term "nucleoside" also encompasses DNA units (or monomers) comprising a 2-deoxyribose unit which is bonded through its number one carbon to a nitrogenous base, such as A, C, T, G or U. The term "nucleoside" also covers variants or analogues of such RNA and DNA monomers. It will be understood that the individual nucleosides are linked together by an internucleoside linkage group.

20

When used in the present context, the terms "locked nucleic acid monomer", "locked nucleic acid residue", "LNA monomer" or "LNA residue" refer to a bicyclic nucleotide analogue. LNA monomers are described in *inter alia* WO 99/14226, WO 00/56746, WO 00/56748, WO 01/25248, WO 02/28875, WO 03/006475 and WO 03/095467. The LNA monomer may also be defined with respect to its chemical formula. Thus, a "LNA monomer" as used herein has the chemical structure shown in Scheme 2 below:

25

Scheme 2



wherein

X is selected from the group consisting of O, S and NR^{H} , where R^{H} is H or alkyl, such as C_{1-4} -alkyl;

5

Y is $(-\text{CH}_2)_r$, where r is an integer of 1-4; with the proviso that when $\text{X}=\text{O}$ then r is not 2.

10

Z and Z^* are independently absent or selected from the group consisting of an internucleoside linkage group, a terminal group and a protection group; and

B is a nucleobase. A detailed disclosure of preferred LNA monomers are given below.

15 The term "internucleoside linkage group" is intended to mean a group capable of covalently coupling together two nucleosides, two LNA monomers, a nucleoside and a LNA monomer, etc. Specific and preferred examples include phosphate groups and phosphorothioate groups.

20 The term "nucleic acid" is defined as a molecule formed by covalent linkage of two or more nucleotides. The terms "nucleic acid" and "polynucleotide" are used interchangeable herein. When used herein, a "nucleic acid" or a "polynucleotide" typically contains more than 35 nucleotides.

25 The term "oligonucleotide" refers, in the context of the present invention, to an oligomer (also called oligo) of RNA, DNA and/or LNA monomers as well as variants and analogues thereof. When used herein, an "oligonucleotide" typically contains 2-35 nucleotides, in particular 12-35 nucleotides.

30 By the term "improved properties" is understood one or more property by which the siLNA compound of the invention show better overall performance as compared to its native counterparts. Examples of such parameters are ease of production, cost of production, longer shelf life, higher binding affinity to target (interim complement in siLNA or mRNA target), higher ability to penetrate a cell membrane, better resistance to extra- and
35 intracellular nucleases, easier to formulate pharmaceutically, higher potency in mode of action, better tissue distribution, better phenotypic response, longer lasting effects, etc.

By the terms "unit" or "residue" is understood a monomer.

The term "at least one" encompasses an integer larger than or equal to 1, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 and so forth.

The terms "a" and "an" as used about a nucleotide, a nucleoside, an active agent, a LNA monomer, etc. is intended to mean one or more. In particular, the expression "a component (such as a nucleotide, a nucleoside, an active agent, a LNA monomer or the like) selected from the group consisting of ..." is intended to mean that one or more of the cited components may be selected. Thus, expressions like "a component selected from the group consisting of A, B and C" is intended to include all combinations of A, B and C, i.e. A, B, C, A+B, A+C, B+C and A+B+C.

The term "thio-LNA" refers to a locked nucleotide in which X in Scheme 2 is S. Thio-LNA can be in both the beta-D form and in the alpha-L form. Generally, the beta-D form of thio-LNA is preferred. The beta-D form of thio-LNA is shown in Scheme 3 as compound **3C**.

The term "amino-LNA" refers to a locked nucleotide in which X in Scheme 2 is NH or NR^H, where R^H is hydrogen or C₁₋₄-alkyl. Amino-LNA can be in both the beta-D form and alpha-L form. Generally, the beta-D form of amino-LNA is preferred. The beta-D form of amino-LNA is shown in Scheme 3 as compound **3D**.

The term "oxy-LNA" refers to a locked nucleotide in which X in Scheme 2 is O. oxy-LNA can be in both the beta-D form and alpha-L form. The beta-D form of oxy-LNA is preferred. The beta-D form and the alpha-L form are shown in Scheme 3 as compounds **3A** and **3B**, respectively.

The term "siLNA" is broadly used about the double-stranded compounds of the invention. Thus, a "siLNA", as used herein, always comprises at least one LNA monomer.

As used herein, the term "siRNA" refers to a double stranded stretch of RNA or modified RNA monomers. In a typical siRNA compound, the two strands usually have 19 nucleotides complementary to each other thereby creating a double strand that is 19 nucleotides long and each strand having a 3'-end of two overhanging nucleotides. This is not a strict definition of siRNA, which may be slightly longer or shorter, and with or without overhangs. In siRNA one strand is guiding and complementary to the target RNA (antisense strand), and the other strand (sense strand) has the same sequence as the target RNA and hence is complementary to the guiding/antisense strand. Herein, regulatory RNAs such as "micro RNA" ("miRNA") and "short RNA" ("shRNA") and a variety of structural RNAs such as tRNA, snRNA, scRNA, rRNA are used interchangeably with the term "siRNA".

As used herein, the term "mRNA" means the presently known mRNA transcript(s) of a targeted gene, and any further transcripts, which may be identified.

- 5 As used herein, the term "target nucleic acid" encompass any RNA that would be subject to modulation, targeted cleavage, steric blockage (decrease the abundance of the target RNA and/or inhibit translation) guided by the antisense strand. The target RNA could, for example, be genomic RNA, genomic viral RNA, mRNA or a pre-mRNA
- 10 As used herein, the term "target-specific nucleic acid modification" means any modification to a target nucleic acid.

- As used herein, the term "gene" means the gene including exons, introns, non-coding 5' and 3' regions and regulatory elements and all currently known variants thereof and any
- 15 further variants, which may be elucidated.

- As used herein, the term "modulation" means either an increase (stimulation) or a decrease (inhibition) in the expression of a gene. In the present invention, inhibition is the preferred form of modulation of gene expression and mRNA is a preferred target.
- 20

- As used herein, the term "targeting" an siRNA or siRNA compound to a particular target nucleic acid means providing the siRNA or siRNA oligonucleotide to the cell, animal or human in such a way that the siRNA or siRNA compounds are able to bind to and modulate the function of the target.
- 25

- As used herein, "hybridisation" means hydrogen bonding, which may be Watson-Crick, Hoogsteen, reversed Hoogsteen hydrogen bonding, etc., between complementary nucleoside or nucleotide bases. The four nucleobases commonly found in DNA are G, A, T and C of which G pairs with C, and A pairs with T. In RNA T is replaced with uracil (U),
- 30 which then pairs with A. The chemical groups in the nucleobases that participate in standard duplex formation constitute the Watson-Crick face. Hoogsteen showed a couple of years later that the purine nucleobases (G and A) in addition to their Watson-Crick face have a Hoogsteen face that can be recognised from the outside of a duplex, and used to bind pyrimidine oligonucleotides via hydrogen bonding, thereby forming a triple helix
- 35 structure.

In the context of the present invention "complementary" refers to the capacity for precise pairing between two nucleotides sequences with one another. For example, if a nucleotide at a certain position of an oligonucleotide is capable of hydrogen bonding with a nucleotide

at the corresponding position of a DNA or RNA molecule, then the oligonucleotide and the DNA or RNA are considered to be complementary to each other at that position. The DNA or RNA strand are considered complementary to each other when a sufficient number of nucleotides in the oligonucleotide can form hydrogen bonds with corresponding nucleotides in the target DNA or RNA to enable the formation of a stable complex. To be stable *in vitro* or *in vivo* the sequence of a siRNA or siRNA compound need not be 100% complementary to its target nucleic acid. The terms "complementary" and "specifically hybridisable" thus imply that the siRNA or siRNA compound binds sufficiently strong and specific to the target molecule to provide the desired interference with the normal function of the target whilst leaving the function of non-target mRNAs unaffected

In the present context the term "conjugate" is intended to indicate a heterogenous molecule formed by the covalent attachment of a compound as described herein to one or more non-nucleotide or non-polynucleotide moieties. Examples of non-nucleotide or non-polynucleotide moieties include macromolecular agents such as proteins, fatty acid chains, sugar residues, glycoproteins, polymers, or combinations thereof. Typically proteins may be antibodies for a target protein. Typical polymers may be polyethelene glycol.

In the present context, the term " C_{1-6} -alkyl" is intended to mean a linear or branched saturated hydrocarbon chain wherein the longest chains has from one to six carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl and hexyl. A branched hydrocarbon chain is intended to mean a C_{1-6} -alkyl substituted at any carbon with a hydrocarbon chain.

In the present context, the term " C_{1-4} -alkyl" is intended to mean a linear or branched saturated hydrocarbon chain wherein the longest chains has from one to four carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl. A branched hydrocarbon chain is intended to mean a C_{1-4} -alkyl substituted at any carbon with a hydrocarbon chain.

When used herein the term " C_{1-6} -alkoxy" is intended to mean C_{1-6} -alkyl-oxy, such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentoxy, isopentoxy, neopentoxy and hexoxy.

In the present context, the term " C_{2-6} -alkenyl" is intended to mean a linear or branched hydrocarbon group having from two to six carbon atoms and containing one or more double bonds. Illustrative examples of C_{2-6} -alkenyl groups include allyl, homo-allyl, vinyl, crotyl, butenyl, butadienyl, pentenyl, pentadienyl, hexenyl and hexadienyl. The position of the unsaturation (the double bond) may be at any position along the carbon chain.

In the present context the term "C₂₋₆-alkynyl" is intended to mean linear or branched hydrocarbon groups containing from two to six carbon atoms and containing one or more triple bonds. Illustrative examples of C₂₋₆-alkynyl groups include acetylene, propynyl, butynyl, pentynyl and hexynyl. The position of unsaturation (the triple bond) may be at any position along the carbon chain. More than one bond may be unsaturated such that the "C₂₋₆-alkynyl" is a di-yne or enedi-yne as is known to the person skilled in the art.

- The term "carcinoma" is intended to indicate a malignant tumor of epithelial origin.
- 10 Epithelial tissue covers or lines the body surfaces inside and outside the body. Examples of epithelial tissue are the skin and the mucosa and serosa that line the body cavities and internal organs, such as intestines, urinary bladder, uterus, etc. Epithelial tissue may also extend into deeper tissue layers to from glands, such as mucus-secreting glands.
- 15 The term "sarcoma" is intended to indicate a malignant tumor growing from connective tissue, such as cartilage, fat, muscles, tendons and bones.

The term "glioma", when used herein, is intended to cover a malignant tumor originating from glial cells.

20

Compounds of the Invention

- The present invention is, in part, based on the surprising finding that LNA can be used to improve RNA interference by incorporating LNA monomers in the sense and/or antisense strand of double-stranded polynucleotides, such as siRNA. This is particularly surprising as
- 25 the structurally closely related ENA monomers strongly deteriorates RNA interference, even for minimally modified siRNAs (Hamada et al., *Antisense and Nucl. Acid Drug Dev.*, 2002, 12, 301-309).

- LNA exhibits unprecedented binding properties towards DNA and RNA target sequences. In
- 30 addition to these remarkable hybridization properties, LNA monomers can be mixed and act cooperatively with DNA and RNA monomers as well as with nucleotide analogues, such as 2'-O-alkyl-modified RNA monomers. The unprecedented binding affinity of LNA towards DNA or RNA target sequences, and the ability to mix LNA monomers freely with DNA and RNA monomers and a range of nucleotide analogues has some important consequences for
- 35 the development of effective and safe siRNA-like compounds.

Natural dsDNA exists at physiological pH as a B-form helix, whereas dsRNA exists as an A-form helix. This morphological difference is due to the difference in the preferred sugar conformations of the deoxyriboses and the riboses. At room temperature the furanose ring

of deoxyribose exists in an equilibrium between C2'-*endo* (*S*-type) and C3'-*endo* (*N*-type) conformation with an energy barrier of ~2 kcal/mol (Fig. 1). The C2'-*endo* (*S*-type) conformation gives rise to the B-form helix, whereas the C3'-*endo* (*N*-type) conformation gives rise to the A-form helix. For deoxyribose the *S*-type conformation is slightly lowered
5 in energy compared to the *N*-type and that explains why DNA is found in the *S*-type conformation. For ribose the *N*-type conformation is preferred and, therefore, RNA adopts the A-form helix. It is known that the A-form helix is associated with higher hybridisation stability.

- 10 LNA monomers are locking the conformation of the furanose ring in a conformation that corresponds to an extreme C3'-*endo* conformation. These monomers are therefore mimicking the RNA conformation, and it has been shown that the structure of the oligonucleotide and duplexes of the monomers are RNA-like (Petersen et al., J. Am. Chem. Soc., 2002, 124, 5974-82). This means that the structure of RNA oligonucleotides and
15 RNA/RNA duplexes in which LNA monomers are incorporated are not significantly changed compared to native RNA oligonucleotides and RNA/RNA duplexes. It was furthermore shown that the LNA monomers induced RNA-like conformation when introduced in DNA. Thus, the LNA monomers imposed, in particular at the 3' end, a strong degree of C3'-*endo* conformation (RNA like). If, for instance, every second or third residue in a DNA oligomer
20 is replaced with LNA monomers, the overall structure of the oligonucleotide will become much like RNA. Thus, the duplex formed by such oligonucleotides will attain a structure resembling native A-form duplexes (RNA/RNA). It is part of this invention to use this property of the LNA monomers to direct the conformation of DNA towards RNA structure.
- 25 It will be appreciated that the unprecedented affinity of the LNA may be used to shorten the usual length of a siRNA oligonucleotide (from 21-35 mers to, e.g., 12-20 mers) without compromising the affinity required for pharmacological activity. As the intrinsic specificity of an oligonucleotide is inversely correlated to its length, such a shortening will significantly increase the specificity of the siLNA compound towards its RNA target. One
30 aim of the invention is therefore, due to the fact that the sequence of the humane genome is available and the annotation of its genes is rapidly progressing, to identify the shortest possible, unique sequences in the target mRNA. Moreover, by reducing the size of the oligonucleotides, and thereby ease the manufacturing process and lowering the manufacturing costs, it is believed that siLNA compounds, such as those disclosed herein,
35 have the potential to become the basis for RNAi therapy, and to become a commercially competitive treatment which may be offered for a variety of diseases.

Accordingly, in its broadest aspect the present invention relates to a double-stranded compound comprising a sense strand and an antisense strand, wherein each strand

comprises 12-35 nucleotides and wherein said compound comprises at least one locked nucleic acid (LNA) monomer. The double-stranded compounds of the invention may be composed entirely of LNA monomers or it may be composed of LNA monomers in any combination with DNA monomer, RNA monomers or nucleotide analogues.

5

As indicated above, the term "nucleotide" means a 2-deoxyribose (DNA) unit or a ribose (RNA) unit which is bonded through its number one carbon to a nitrogenous base, such as adenine (A), cytosine (C), thymine (T), guanine (G) or uracil (U), and which is bonded through its number five carbon atom to an internucleoside linkage group (as defined

10 above) or to a terminal group (as discussed below). Thus, the term "nucleotide" encompasses RNA units (or monomers) comprising a ribose unit which is bonded through its number one carbon to a nitrogenous base, such as A, C, T, G or U, and which is bonded through its number five carbon atom to a phosphate group or to a terminal group. As explained above, the term "nucleotide" also encompasses DNA units (or monomers)

15 comprising a 2-deoxyribose unit which is bonded through its number one carbon to a nitrogenous base, such as A, C, T, G or U, and which is bonded through its number five carbon atom to a phosphate group or to a terminal group. The term "nucleotide" also covers variants or analogues of such RNA and DNA monomers. For example, the 2'-OH (RNA) or 2'-H (DNA) group may be substituted with -O-CH₃, -O-CH₂-CH₂-OCH₃, -O-CH₂-CH₂-CH₂-NH₂, -O-CH₂-CH₂-CH₂-OH or F. Other examples of a nucleotide analogues are LNA


20 monomers. Also, the internucleoside linkage group is not limited to phosphate (-O-P(O)₂-O-), but may include -O-P(O,S)-O-, -O-P(S)₂-O-, -S-P(O)₂-O-, -S-P(O,S)-O-, -S-P(S)₂-O-, -O-P(O)₂-S-, -O-P(O,S)-S-, -S-P(O)₂-S-, -O-PO(R^H)-O-, O-PO(OCH₃)-O-, -O-PO(NR^H)-O-, -O-PO(OCH₂CH₂S-R)-O-, -O-PO(BH₃)-O-, -O-PO(NHR^H)-O-, -O-P(O)₂-NR^H-, -NR^H-P(O)₂-O-,

25 -NR^H-CO-O-, -NR^H-CO-NR^H-, -O-CO-O-, -O-CO-NR^H-, -NR^H-CO-CH₂-, -O-CH₂-CO-NR^H-, -O-CH₂-CH₂-NR^H-, -CO-NR^H-CH₂-, -CH₂-NR^H-CO-, -O-CH₂-CH₂-S-, -S-CH₂-CH₂-O-, -S-CH₂-CH₂-S-, -CH₂-SO₂-CH₂-, -CH₂-CO-NR^H-, -O-CH₂-CH₂-NR^H-CO-, -CH₂-NCH₃-O-CH₂-, where R^H is hydrogen or C₁₋₄-alkyl. Furthermore, the nitrogenous base is not restricted to A, C, T, G or U, but may include other purines and pyrimidines, such as 5-methylcytosine,

30 isocytosine, pseudoisocytosine, 5-bromouracil, 5-propynyluracil, 5-propyny-6-fluoroluracil, 5-methylthiazoleuracil, 6-aminopurine, 2-aminopurine, inosine, 2,6-diaminopurine, 7-propyne-7-deazaadenine, 7-propyne-7-deazaguanine and 2-chloro-6-aminopurine. Other examples of nucleotide variants and analogues which fall within the present definition of "nucleotide" are described in Freier & Altmann (Nucl. Acid Res., 1997, 25, 4429-4443) and

35 Uhlmann (Curr. Opinion in Drug & Development (2000, 3(2): 293-213). Scheme 1 below illustrates selected examples of such nucleotide variants and analogous. In conclusion, the compounds of the invention may contain any of the above-mentioned nucleotides as long as the compound contains at least one LNA monomer in at least one of the strands.


Scheme 1



As indicated above, the term "locked nucleic acid monomer" or "LNA monomer" refers to a bicyclic nucleotide analogue and has the chemical structure shown in Scheme 2 below:

17

Scheme 2



wherein

10 X is selected from the group consisting of O, S and NR^{H} , where R^{H} is H or alkyl, such as C_{1-4} -alkyl;


Y is $(-\text{CH}_2)_r$, where r is an integer of 1-4; with the proviso that when $\text{X}=\text{O}$ then r is not 2.


15 Z and Z^* are independently absent or selected from the group consisting of an internucleoside linkage group, a terminal group and a protection group; and

B is a nucleobase.

20 In a preferred embodiment of the invention, r is 1, i.e. a preferred LNA monomer has the chemical structure shown in Scheme 3 below:

Scheme 3






wherein Z, Z*, R^H and B are defined above.

- 10 In an even more preferred embodiment of the invention, X is O and r is 1, i.e. an even more preferred LNA monomer has the chemical structure shown in Scheme 4 below:

Scheme 4



- 20 wherein Z, Z* and B are defined above.

The structures shown in **3A** and **3B** above may also be referred to as the "beta-D form" and the "alpha-L form", respectively. In a highly preferred embodiment of the invention, the LNA monomer is the beta-D form, i.e. the LNA monomer has the chemical structure

25 indicated in **3A** above.

As indicated above, Z and Z*, which serve for an internucleoside linkage, are independently absent or selected from the group consisting of an internucleoside linkage group, a terminal group and a protection group depending on the actual position of the LNA monomer within the compound. It will be understood that in embodiments where the LNA monomer is located at the 3' end, Z is a terminal group and Z* is an internucleoside linkage. In embodiments where the LNA monomer is located at the 5' end, Z is absent and Z* is a terminal group. In embodiments where the LNA monomer is located within the nucleotide sequence, Z is absent and Z* is an internucleoside linkage group.

- Specific examples of internucleoside linkage groups include -O-P(O)₂-O-, -O-P(O,S)-O-, -O-P(S)₂-O-, -S-P(O)₂-O-, -S-P(O,S)-O-, -S-P(S)₂-O-, -O-P(O)₂-S-, -O-P(O,S)-S-, -S-P(O)₂-S-, -O-PO(R^H)-O-, O-PO(OCH₃)-O-, -O-PO(NR^H)-O-, -O-PO(OCH₂CH₂S-R)-O-, -O-PO(BH₃)-O-, -O-PO(NHR^H)-O-, -O-P(O)₂-NR^H-, -NR^H-P(O)₂-O-, -NR^H-CO-O-, -NR^H-CO-NR^H-, -O-CO-O-, -O-CO-NR^H-, -NR^H-CO-CH₂-, -O-CH₂-CO-NR^H-, -O-CH₂-CH₂-NR^H-, -CO-NR^H-CH₂-, -CH₂-NR^H-CO-, -O-CH₂-CH₂-S-, -S-CH₂-CH₂-O-, -S-CH₂-CH₂-S-, -CH₂-SO₂-CH₂-, -CH₂-CO-NR^H-, -O-CH₂-CH₂-NR^H-CO-, -CH₂-NCH₃-O-CH₂-, where R^H is hydrogen or C₁₋₄-alkyl.

In a preferred embodiment of the invention, the internucleoside linkage group is a phosphate group (-O-P(O)₂-O-), a phosphorothioate group (-O-P(O,S)-O-) or the compound may contain both phosphate groups and phosphorothioate groups.

- Specific examples of terminal groups include terminal groups selected from the group consisting of hydrogen, azido, halogen, cyano, nitro, hydroxy, Prot-O-, Act-O-, mercapto, Prot-S-, Act-S-, C₁₋₆-alkylthio, amino, Prot-N(R^H)-, Act-N(R^H)-, mono- or di(C₁₋₆-alkyl)amino, optionally substituted C₁₋₆-alkoxy, optionally substituted C₁₋₆-alkyl, optionally substituted C₂₋₆-alkenyl, optionally substituted C₂₋₆-alkenyloxy, optionally substituted C₂₋₆-alkynyl, optionally substituted C₂₋₆-alkynyloxy, monophosphate including protected monophosphate, monothiophosphate including protected monothiophosphate, diphosphate including protected diphosphate, dithiophosphate including protected dithiophosphate, triphosphate including protected triphosphate, trithiophosphate including protected trithiophosphate, where Prot is a protection group for -OH, -SH and -NH(R^H), and Act is an activation group for -OH, -SH, and -NH(R^H), and R^H is hydrogen or C₁₋₆-alkyl.

Examples of phosphate protection groups include S-acetylthioethyl (SATE) and S-pivaloylthioethyl (t-butyl-SATE).

Still further examples of terminal groups include DNA intercalators, photochemically active groups, thermochemically active groups, chelating groups, reporter groups, ligands, carboxy, sulphono, hydroxymethyl, Prot-O-CH₂-, Act-O-CH₂-, aminomethyl, Prot-N(R^H)-

CH₂-, Act-N(R^H)-CH₂-, carboxymethyl, sulphonomethyl, where Prot is a protection group for -OH, -SH and -NH(R^H), and Act is an activation group for -OH, -SH, and -NH(R^H), and R^H is hydrogen or C₁₋₆-alkyl.

- 5 Examples of protection groups for -OH and -SH groups include substituted trityl, such as 4,4'-dimethoxytrityloxy (DMT), 4-monomethoxytrityloxy (MMT); trityloxy, optionally substituted 9-(9-phenyl)xanthenyloxy (pixyl), optionally substituted methoxytetrahydro-
 10 pyraniloxy (mthp); silyloxy, such as trimethylsilyloxy (TMS), triisopropylsilyloxy (TIPS), *tert*-butyldimethylsilyloxy (TBDMS), triethylsilyloxy, phenyldimethylsilyloxy; *tert*-
 15 butylethers; acetals (including two hydroxy groups); acyloxy, such as acetyl or halogen-substituted acetyls, *e.g.* chloroacetyloxy or fluoroacetyloxy, isobutyryloxy, pivaloyloxy, benzoyloxy and substituted benzoyls, methoxymethyloxy (MOM), benzyl ethers or substituted benzyl ethers such as 2,6-dichlorobenzoyloxy (2,6-Cl₂Bzl). Moreover, when Z or Z* is hydroxyl they may be protected by attachment to a solid support, optionally through
 20 a linker.

- Examples of amine protection groups include fluorenylmethoxycarbonylamino (Fmoc), *tert*-
 butyloxycarbonylamino (BOC), trifluoroacetylamino, allyloxycarbonylamino (alloc, AOC), Z-
 benzyloxycarbonylamino (Cbz), substituted benzyloxycarbonylamino, such as 2-chloro
 20 benzyloxycarbonylamino (2-ClZ), monomethoxytritylamino (MMT), dimethoxytritylamino (DMT), phthaloylamino, and 9-(9-phenyl)xanthenylamino (pixyl).

- The activation group preferably mediates couplings to other residues and/or nucleotide monomers and after the coupling has been completed the activation group is typically
 25 converted to an internucleoside linkage. Examples of such activation groups include optionally substituted O-phosphoramidite, optionally substituted O-phosphotriester, optionally substituted O-phosphordiester, optionally substituted H-phosphonate, and optionally substituted O-phosphonate. In the present context, the term "phosphoramidite" means a group of the formula -P(OR^x)-N(R^y)₂, wherein R^x designates an optionally
 30 substituted alkyl group, *e.g.* methyl, 2-cyanoethyl, or benzyl, and each of R^y designates optionally substituted alkyl groups, *e.g.* ethyl or isopropyl, or the group -N(R^y)₂ forms a morpholino group (-N(CH₂CH₂)₂O). R^x preferably designates 2-cyanoethyl and the two R^y are preferably identical and designates isopropyl. Accordingly, a particularly preferred phosphoramidite is N,N-diisopropyl-O-(2-cyanoethyl)phosphoramidite.

35

As indicated above, B is a nucleobase which may be of natural or non-natural origin. Specific examples of nucleobases include adenine (A), cytosine (C), 5-methylcytosine (MeC), isocytosine, pseudoisocytosine, guanine (G), thymine (T), uracil (U), 5-bromouracil, 5-propynyluracil, 5-propynyl-6-fluoroluracil, 5-methylthiazoleuracil, 6-aminopurine, 2-

aminopurine, inosine, 2,6-diaminopurine, 7-propyne-7-deazaadenine, 7-propyne-7-deazaguanine and 2-chloro-6-aminopurine. Preferred nucleobases include A, C, ^{Me}C, G, T and U, in particular A, C, ^{Me}C, G and U.

- 5 In one embodiment of the invention, the sense strand comprises at least one LNA monomer, such as 1-10 LNA monomers, e.g. 1-5 LNA monomers. In another embodiment of the invention, the antisense strand comprises at least one LNA monomer, such as 1-10 LNA monomers, e.g. 1-5 LNA monomers. In a further embodiment of the invention, the sense strand comprises at least one LNA monomer and the antisense strand comprises at
- 10 least one LNA monomer. For example, the sense strand typically comprises 1-10 LNA monomers, such as 1-5 LNA monomers, and the antisense strand typically comprises 1-10 LNA monomers, such as 1-5 LNA monomers.

- One particular advantage about the compounds of the invention is their improved stability
- 15 in biological fluids, such as serum. Thus, one embodiment of the invention includes the incorporation of LNA monomers into a standard DNA or RNA oligonucleotide to increase the stability of the resulting siLNA compound in biological fluids e.g. through the increase of resistance towards nucleases (endonucleases and exonucleases). Accordingly, the compounds of the invention will, due to incorporation of LNA monomers, exhibit an
- 20 increased circulation half-life as a result of its increased melting temperature and/or its increased nuclease resistance. The extent of stability will depend on the number of LNA monomers used, their position in the oligonucleotides and the type of LNA monomer used. Compared to DNA and phosphorothioates the following order of ability to stabilise an oligonucleotide against nucleolytic degradation can be established: DNA < <
- 25 phosphorothioates, LNA-phosphordiester < LNA- phosphorothioates.

- Therefore, compounds according to the invention which are particularly preferred are such compounds which, when incubated in serum (e.g. human, bovine or mice serum), such as in 10% foetal bovine serum in a physiological salt solution at 37°C for 5 hours, are
- 30 degraded to a lesser extent than the corresponding dsRNA compound. Preferably, less than 25% of the initial amount of the compound of the invention is degraded after 5 hours, more preferably less than 50% of the initial amount of the compound of the invention is degraded after 5 hours, even more preferably less than 75% of the initial amount of the compound of the invention is degraded after 5 hours. In another embodiment, it is
- 35 preferred that less than 25% of the initial amount of the compound of the invention is degraded after 10 hours, and even more preferred that less than 50% of the initial amount of the compound of the invention is degraded after 10 hours.

Given the fact that LNA synthesis is compatible with standard RNA/DNA synthesis and that the LNA monomers mix freely with many contemporary nucleic acid analogues, nuclease resistance of siRNA compounds can be further enhanced according to the invention by either incorporating other analogues that display increased nuclease stability or by
5 exploiting nuclease-resistant internucleoside linkages e.g. phosphoromonothioate, phosphorodithioate, and methylphosphonate linkages, etc.

LNA monomers can be used freely in the design of siRNA at both 3' overhangs and the 5' end of the sense strand with full activation of the siRNA effect and down-regulation of
10 protein production (>90% reduction). LNA monomers can be distributed quite freely over the sense strand in the siRNA with maintaining high down-regulating capability (80% reduction). The 5' end of the antisense strand in the siRNA can also be modified by LNA monomers, thereby giving rise to down-regulatory capabilities of up to 50-70%. Using a highly LNA monomer-substituted antisense strand does not seem to give a down-
15 regulatory effect, although it can not be ruled out that special design of that combination can elicit a RNAi effect. LNA monomer substitutions of the 3' overhangs along with the 5' end of the sense strand of the siRNA give the highest reduction of protein levels. The 5' end of the antisense strand is the most sensitive to the LNA monomer modification while many other sites of modification are better tolerated.

20

In one embodiment the siRNA compound is designed so that the LNA monomers are incorporated in the compound in such a way that they are strengthening the basepairs in the duplex at the 5' end of the sense strand. The helicase can there by be directed to unwind from the other 5' end (antisense strand 5' end). In this way the incorporation of
25 the antisense/guiding strand into RISC can be controlled. The helicase starts unwinding the siRNA duplex at the weakest binding end. The released 3' end is probably targeted for degradation while the remaining strand is incorporated in the RISC. Efficient siRNAs show accumulation of the antisense/guiding strand and weaker base pairing in the 5' end of the antisense/guiding strand. Unwanted side effects may possibly be avoided by having only
30 the correct strand (the antisense/guiding strand) in RISC and not the unwanted sense strand (not complementary to the desired target RNA).

The effect of incorporating LNA-monomers in the 5' end of the antisense strand can be seen from Fig. 11. The RNAi-impeding effect of a LNA residue in the 5'-end can partially be
35 removed by incorporating an opposite mismatch. In Fig. 11 this has been shown for both the Renilla and Firefly targets.

The RNAi-impeding effect of a LNA monomer incorporated at the 5' end of the antisense strand can be almost eliminated by moving the LNA monomer one base position towards

the 3' end (Fig. 12). Moving the LNA-monomer further towards the 3' end of the antisense strand does not affect the gene expression, but when the LNA monomer takes up position 10 or 12 a significant decrease in the RNAi effect is observed. The RISC complex will cleave the mRNA at a position opposite the position between 10 and 11 of the antisense strand of the siRNA and, apparently, incorporation of the synthetic LNA monomer at that site impedes the cleavage by the RISC complex. When the LNA monomer is moved further along the antisense strand this impeding effect is decreased.

As described above the helicase exhibits strand bias and will preferably incorporate siRNA from the weakest binding end of the siRNA. Therefore, in principle, both strands in the siRNA duplex can be incorporated. This among other properties of the RISC+siRNA system will give rise to off-target effects. One way of reducing this is to incorporate the high affinity LNA monomers. For the Ren1 site the 5'-nucleobase in the antisense strand is U that constitutes a "low" binding residue. The RISC complex will therefore read from this side and incorporate the antisense strand (the correct strand). For the Ren2 and Ren3 sites the 5'-nucleobase is C that constitutes "high" binding sites. For these sites the 5' end of the sense strand is positioned by an A and a U nucleobase that both constitutes "low" binding sites. The RISC can therefore exhibit strand bias in this case and read partially from the sense strand (the wrong strand). By replacing the 5'-adenosine and uridine residues with the corresponding A- and U-LNA residues, the strand bias is removed and the antisense strand is incorporated in the RISC complex (Fig. 13). Accordingly, LNA residues can decrease strand bias and increase the potency of the duplex. The siLNA according to the present invention preferably has an antisense sequence, which has least 70%, more preferably 90-100% sequence identity to the target molecule.

25

As indicated above several particular designs augment the overall potency applicability of native siRNA:

(a) "end capping" of the siRNA with LNA improves the nuclease stability (Figs. 2 and 15).

30

(b) Placing a LNA monomer towards the 5'-end of the sense strand improves the potency of the siLNA compared to native siRNA ("locking"). This is illustrated by the potency increase for medium efficient targets (Figs. 13 and 15).

35

(c) In the "LNA walk" (Fig. 12) it is shown that placing a LNA monomer at the cleavage site of the RISC complex, e.g. at position 10, calculated from the 5' end in the antisense strand, decreases the activity of the siRNA ("blocking").

These basic observations are important for improving the overall potency of siRNA. In optimised designs the 3' ends should be "capped" with LNA monomers thereby securing nuclease resistance (Figs. 12 and 15). The 5' end of the sense strand should also be LNA modified to increase binding to the antisense strand and thereby direct the helicase to incorporate from the "correct side" of the duplex. Such "locking" of the sense 5' end sense/antisense 3' side of the duplex can be done by incorporating at least one LNA monomer at either side of the duplex. Such modified duplexes may also contain LNA-LNA hydrogen bonding bases. The observation that gene silencing is reduced when LNA is incorporated in position 10 or 12 in the antisense strand can be used in the reversed scenario. If the RISC complex should incorporate part of the sense strand and thereby lead to unwanted off-target effects the potency of the unwanted incorporation could be reduced by incorporating LNA at position 10 and 12 in the sense strand ("blocking") as shown in Fig 12.

Accordingly, in an interesting embodiment of the invention, the sense strand comprises at least one LNA monomer located in at least one (such as one) of the positions 9-13, counted from the 5' end. Preferably, the sense strand comprises at least one LNA monomer located in at least one (such as one) of the positions 10-12, counted from the 5' end. In a particular interesting embodiment of the invention the sense strand comprises a LNA monomer in position 10, position 12 or in both of position 10 and 12, counted from the 5' end. Furthermore, it is particularly preferred that the LNA monomer, if incorporated in position 10, contains a nitrogenous base which is different from the naturally-occurring RNA bases, i.e. different from A, C, G and U. In a particular preferred embodiment the LNA monomer located at position 10 (counted from the 5' end) contains the nitrogenous base T.

It is known that LNA monomers incorporated into oligos will induce a RNA-like structure of the oligo and the hybrid that it may form. It has also been shown that LNA residues modify the structure of DNA residues, in particular when the LNA residues is incorporated in the proximity of 3' end. LNA monomer incorporation towards the 5' end seems to have a smaller effect. This means that it is possible to modify RNA strands which contain DNA monomers, and if one or more LNA residues flank the DNA monomers they too will attain a RNA-like structure. Therefore, DNA and LNA monomer can replace RNA monomers and still the oligo will attain an overall RNA-like structure. As DNA monomers are considerably cheaper than RNA monomers, easier to synthesise and more stable towards nucleolytic degradation, such modifications will therefore improve the overall use and applicability of siRNAs (see, e.g., Fig. 15).

Accordingly, it is preferred that at least one (such as one) LNA monomer is located at the 5' end of the sense strand. More preferably, at least two (such as two) LNA monomers are located at the 5' end of the sense strand.

- 5 In another preferred embodiment of the invention, the sense strand comprises at least one (such as one) LNA monomer located at the 3' end of the sense strand. More preferably, at least two (such as two) LNA monomers are located at the 3' end of the sense strand.
- 10 In a particular preferred embodiment of the invention, the sense strand comprises at least one (such as one) LNA monomer located at the 5' end of the sense strand and at least one (such as one) LNA monomer located at the 3' end of the sense strand. Even more preferably, the sense strand comprises at least two (such as two) LNA monomers located at the 5' end of the sense strand and at least two (such as two) LNA monomers located at
- 15 the 3' end of the sense strand.

- It is preferred that at least one (such as one) LNA monomer is located at the 3' end of the antisense strand. More preferably, at least two (such as two) LNA monomers are located at the 3' end of the antisense strand. Even more preferably, at least three (such as three)
- 20 LNA monomers are located at the 3' end of the antisense strand. In a particular preferred embodiment of the invention, no LNA monomer is located at or near (i.e. within 1, 2, or 3 nucleotides) the 5' end of the antisense strand.

- Thus, in a further embodiment of the invention, the LNA monomer may be located in any
- 25 position of the sense and antisense strands, except for the 5' end of the antisense strand.

- In a highly preferred embodiment of the invention, the sense strand comprises at least one LNA monomer at the 5' end and at least one LNA monomer at the 3' end, and the antisense strand comprises at least one LNA monomer at the 3' end. More preferably, the
- 30 sense strand comprises at least one LNA monomer at the 5' end and at least one LNA monomer at the 3' end, and the antisense strand comprises at least two LNA monomers at the 3' end. Even more preferably, the sense strand comprises at least two LNA monomers at the 5' end and at least two LNA monomers at the 3' end, and the antisense strand comprises at least two LNA monomers at the 3' end. Still more preferably, the sense
- 35 strand comprises at least two LNA monomers at the 5' end and at least two LNA monomers at the 3' end, and the antisense strand comprises at least three LNA monomers at the 3' end. It will be understood that in the most preferred embodiment, none of the above-mentioned compounds contain a LNA monomer which is located at the 5' end of the antisense strand.

In a further interesting embodiment of the invention, the LNA monomer is located close to the 3' end, i.e. at position 2, 3 or 4, preferably at position 2 or 3, in particular at position 2, calculated from the 3' end.

5

Accordingly, in a further very interesting embodiment of the invention, the sense strand comprises a LNA monomer located at position 2, calculated from the 3' end. In another embodiment, the sense strand comprises LNA monomers located at position 2 and 3, calculated from the 3' end.

10

In a particular preferred embodiment of the invention, the sense strand comprises at least one (such as one) LNA monomer located at the 5' end and a LNA monomer located at position 2 (calculated from the 3' end). In a further embodiment, the sense strand comprises at least two (such as two) LNA monomers located at the 5' end of the sense
15 strand a LNA monomer located at positions 2 (calculated from the 3' end).

Furthermore, it is preferred that the antisense strand comprises a LNA monomer at position 2, calculated from the 3' end. More preferably, the antisense strand comprises LNA monomers in position 2 and 3, calculated from the 3' end. Even more preferably, the
20 antisense strand comprises LNA monomers located at position 2, 3 and 4, calculated from the 3' end. In a particular preferred embodiment of the invention, no LNA monomer is located at or near (i.e. within 1, 2, or 3 nucleotides) the 5' end of the antisense strand.

In a highly preferred embodiment of the invention, the sense strand comprises at least one
25 LNA monomer at the 5' end and a LNA monomer at position 2 (calculated from the 3' end), and the antisense strand comprises a LNA monomer located at position 2 (calculated from the 3' end). More preferably, the sense strand comprises at least one LNA monomer at the 5' end and a LNA monomer at position 2 (calculated from the 3' end), and the antisense strand comprises LNA monomers at position 2 and 3 (calculated from the 3' end). Even
30 more preferably, the sense strand comprises at least two LNA monomers at the 5' end and LNA monomers at position 2 and 3 (calculated from the 3' end), and the antisense strand comprises LNA monomers at position 2 and 3 (calculated from the 3' end). Still more preferably, the sense strand comprises at least two LNA monomers at the 5' end and LNA monomers at position 2 and 3 (calculated from the 3' end), and the antisense strand
35 comprises LNA monomers at position 2, 3 and 4 (calculated from the 3' end). It will be understood that in the most preferred embodiment, none of the above-mentioned compounds contain a LNA monomer which is located at the 5' end of the antisense strand.

As indicated above, each strand comprises 12-35 nucleotides. It will be understood that these numbers refer to the total number of naturally occurring nucleotides, nucleotide variants and analogues, LNA monomers, etc., in the strand. Thus, the total number of such naturally occurring nucleotides, nucleotide variants and analogues, LNA monomers, etc.,
5 will not be lower than 12 and will not exceed 35. In an interesting embodiment of the invention, each strand comprises 17-25 nucleotides, such as 20-22 or 20-21 nucleotides.

The compounds according to the invention may be blunt ended, and in one particular embodiment the siRNA compound of the invention is a 19-mer and blunt ended. More
10 preferably, however, at least one of the strands has a 3' overhang. Typically, the 3' overhang will be of 1-7 nucleotides (or nucleotide variants or analogues or LNA monomers), preferably of 1-3 nucleotides. Thus, it will be understood that the sense strand may contain a 3' overhang, the antisense strand may contain a 3' overhang, or both of the sense and antisense strands may contain 3' overhangs.

15 In a similar way, at least one of the strands may have a 5' overhang. Typically, the 5' overhang will be of 1-4 nucleotides (or nucleotide variants or analogues or LNA monomers), preferably of 1-3 nucleotides. Thus, it will be understood that the sense strand may contain a 5' overhang, the antisense strand may contain a 5' overhang, or both
20 of the sense and antisense strands may contain 5' overhangs. Evidently, the sense strand may contain both a 3' and a 5' overhang. Alternatively, the antisense strand may contain both a 3' and a 5' overhang.

Typically, the compounds of the invention will contain other residues than LNA monomers.
25 Such other residues may be any of the residues discussed in connection with the definition of "nucleotide" above, and include, for example, native RNA monomers, native DNA monomers as well as nucleotide variants and analogues such as those mentioned in connection with the definition of "nucleotide" above. Specific examples of such nucleotide variants and analogues include, 2'-F, 2'-O-Me, 2'-O-methoxyethyl (MOE), 2'-O-(3-
30 aminopropyl) (AP), hexitol nucleic acid (HNA), 2'-F-arabino nucleic acid (2'-F-ANA) and D-cyclohexenyl nucleoside (CeNA). Furthermore, the internucleoside linkage may be a phosphorodiester, phosphorothioate or N3'-P5' phosphoroamidate internucleoside linkages as described above.

35 In general, the individual strands of the compounds of the invention will contain at least about 5%, at least about 10%, at least about 15% or at least about 20% LNA monomer, based on total number of nucleotides in the strand. In certain embodiments, the compounds of the invention will contain at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about

80% or at least about 90% LNA monomer, based on total number of nucleotides in the strand.

As far as the LNA monomers are concerned, it will be understood that any of the LNA monomers shown in Scheme 2 and 3 are useful for the purposes of the present invention. However, it is currently preferred that the LNA monomer is in the beta-D form, corresponding to the LNA monomers shown as compounds **3A**, **3C** and **3D**. The currently most preferred LNA monomer is the monomer shown as compound **3A** in Scheme 3 and 4 above, i.e. the currently most preferred LNA monomer is the beta-D form of oxy-LNA.

10

In a further embodiment of the invention, the compound of the invention is linked to one or more ligands so as to form a conjugate. The ligand(s) serve(s) the role of increasing the cellular uptake of the conjugate relative to the non-conjugated compound. This conjugation can take place at the terminal 5'-OH and/or 3'-OH positions, but the conjugation may also take place at the sugars and/or the nucleobases. In particular, the growth factor to which the antisense oligonucleotide may be conjugated, may comprise transferrin or folate. Transferrin-polylysine-oligonucleotide complexes or folate-polylysine-oligonucleotide complexes may be prepared for uptake by cells expressing high levels of transferrin or folate receptor. Other examples of conjugates/ligands are cholesterol moieties, duplex intercalators such as acridine, poly-L-lysine, "end-capping" with one or more nuclease-resistant linkage groups such as phosphoromonothioate, and the like.

15

The preparation of transferrin complexes as carriers of oligonucleotide uptake into cells is described by Wagner et al, Proc. Natl. Acad. Sci. USA 87, 3410-3414 (1990). Cellular delivery of folate-macromolecule conjugates via folate receptor endocytosis, including delivery of an antisense oligonucleotide, is described by Low et al, US 5,108,921 and by Leamon et al., Proc. Natl. Acad. Sci. 88, 5572 (1991).

25

The compounds or conjugates of the invention may also be conjugated or further conjugated to active drug substances, for example, aspirin, ibuprofen, a sulfa drug, an antidiabetic, an antibacterial agent, a chemotherapeutic agent or an antibiotic.

30

The native RNA nucleobases are A, C, G and U. Using these in LNA monomers will constitute a minimal modification. However, the bases ^{Me}C (5' methyl cytosine) and T (thymine) are readily used as LNA monomers and can also be used in siLNA duplexes as shown herein (see Fig. 16). It is anticipated that the nature of the bases used in the ends of the siLNA will not significantly affect the functionality of the siRNA molecule as long as they maintain their ability to hybridize to complementary bases if they occupy a base paired position in the molecule. However, when the LNA modifications are placed at internal

35

- positions of the duplex, e.g. at position 10 (calculated from the 5' end), it must be anticipated that the nature of the nucleobase is important. Thus, the native bases, C and U, will perturb the duplex to a smaller degree than the base modifications, T and ^{Me}C. This provides subtle design possibilities. For instance if it is wanted to "block" the sense strand
- 5 in the cleavage site e.g. at the 10th position T or ^{Me}C should be used (if complementary), but if it is needed to modify the antisense strand at the cleavage site e.g. position 10 U or C should be used (if complementary). One embodiment of the invention is therefore to include a modified nucleobase. An impediment of the nucleobase could be obtained by using bulkier groups than methyl, e.g. ethyl, propyl, phenyl or reporter groups like biotin.
- 10 Thus, the differentiated recognition of the nucleobases by the RISC complex, or other enzymes provides an extra level of design opportunities of LNA modified siRNA. Accordingly, in an interesting embodiment of the invention, position 10 (calculated from the 5' end) comprises T or ^{Me}C.
- 15 In order to enable a rapid response to environmental and other changes, biological systems are typically constructed as dynamic systems, i.e. as systems in which the equilibrium state is maintained by the action of both activators and deactivators. Concerning the RISC complex it may therefore be anticipated that the activated complex (i.e. the protein complex containing the intact oligonucleotide that catalyses the
- 20 destruction of the target) is subject to a deactivating activity, such as for instance a nuclease activity that removes all or part of the oligonucleotide thereby disabling the function of the activated RISC complex. Alternatively, deactivation of the RISC complex may simply be determined by the off-rate of the oligonucleotide from the RISC complex, which, after dissociation, may not be able to re-associate.
- 25 Accordingly, in one interesting aspect the present invention relates to the use of the compounds disclosed herein for enhancing the life-time of the active RISC complex thereby enhancing its duration-of-action. In one embodiment of the invention this is achieved by increasing the resistance of the RNA component of the RISC complex to degradation by the
- 30 putative RNase activity(ies) by incorporation of LNA and/or other nucleic acids analogues and/or by chemical modifications. In another embodiment of the invention the desired enhancement of the life-time of the active RISC complex is achieved by decreasing the off-rate of the RNA oligonucleotide from the RISC complex through introduction of LNA and/or other nucleic acid analogues and/or by chemical modifications that increases the affinity of
- 35 the oligonucleotide for its binding partners in the RISC complex.

When designed as an inhibitor, the siLNAs of the invention bind to the target nucleic acid and modulate the expression of its cognate protein. Preferably, such modulation produces an inhibition of expression of at least 10% or at least 20% compared to the normal

expression level, more preferably at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% inhibition compared to the normal expression level.

5 Manufacture

The compounds of the invention may be produced using the polymerisation techniques of nucleic acid chemistry, which is well known to a person of ordinary skill in the art of organic chemistry. Generally, standard oligomerisation cycles of the phosphoramidite approach (S. L. Beaucage and R. P. Iyer, *Tetrahedron*, 1993, 49, 6123; and S. L.

- 10 Beaucage and R. P. Iyer, *Tetrahedron*, 1992, 48, 2223) may be used, but other chemistries, such as the H-phosphonate chemistry or the phosphotriester chemistry may also be used.

- For some monomers longer coupling time and/or repeated couplings with fresh reagents
15 and/or use of more concentrated coupling reagents may be necessary. However, in our hands, the phosphoramidites employed coupled with a satisfactory >97% step-wise coupling yield. Thiolation of the phosphate may be performed by exchanging the normal oxidation, i.e. the iodine/pyridine/H₂O oxidation, with an oxidation process using Beaucage's reagent (commercially available). As will be evident to the skilled person, other
20 sulphurisation reagents may be employed.

- Purification of the individual strands may be done using disposable reversed phase purification cartridges and/or reversed phase HPLC and/or precipitation from ethanol or butanol. Gel electrophoresis, reversed phase HPLC, MALDI-MS, and ESI-MS may be used
25 to verify the purity of the synthesised LNA-containing oligonucleotides. Furthermore, solid support materials having immobilised thereto a nucleobase-protected and 5'-OH protected LNA are especially interesting for synthesis of the LNA-containing oligonucleotides where a LNA monomer is included at the 3' end. For this purpose, the solid support material is preferable CPG or polystyrene onto which a 3'-functionalised, optionally nucleobase
30 protected and optionally 5'-OH protected LNA monomer is linked. The LNA monomer may be attached to the solid support using the conditions stated by the supplier for that particular solid support material.

- One aspect of the present invention is directed to a novel method for synthesis of the
35 compounds of the invention, which is characterised in that the individual monomers, e.g. the LNA monomers and RNA monomers, are coupled using 1*H*-tetrazole or 5-ethylthio-1*H*-tetrazole. A further embodiment of this aspect is that the method involves a coupling time which is in the range of 200-1200 second, such as in the range of 400-1200 seconds, preferably in the range of 600-900 seconds.

The targets to be modified according to the present invention may be targets involved in a number of basic biological mechanisms including red blood cell proliferation, cellular proliferation, ion metabolism, glucose and energy metabolism, pH regulation and matrix
5 metabolism. The invention described herein encompasses a method of preventing or treating cancer comprising a therapeutically effective amount of a target modulating siRNA compound to a human in need of such therapy.

Therapy and Pharmaceutical Compositions

- 10 As explained initially, the compounds of the invention will constitute suitable drugs with improved properties. The design of a potent and safe RNAi drug requires the fine-tuning of diverse parameters such as affinity/specificity, stability in biological fluids, cellular uptake, mode of action, pharmacokinetic properties and toxicity.
- 15 Accordingly, in a further aspect the present invention relates to a pharmaceutical composition comprising a compound according to the invention and a pharmaceutically acceptable diluent, carrier or adjuvant.

In a still further aspect the present invention relates to a compound according to the
20 invention for use as a medicament.

As will be understood dosing is dependent on severity and responsiveness of the disease state to be treated, and the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of the disease state is achieved. Optimal
25 dosing schedules can be calculated from measurements of drug accumulation in the body of the patient. Optimum dosages may vary depending on the relative potency of individual siLNAs. Generally it can be estimated based on EC50s found to be effective in *in vitro* and *in vivo* animal models. In general, dosage is from 0.01 µg to 1 g per kg of body weight, and may be given once or more daily, weekly, monthly or yearly, or even once every 2 to
30 10 years or by continuous infusion for hours up to several months. The repetition rates for dosing can be estimated based on measured residence times and concentrations of the drug in bodily fluids or tissues. Following successful treatment, it may be desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state.

35 Pharmaceutical Composition

It should be understood that the invention also relates to a pharmaceutical composition, which comprises at least one compound of the invention as an active ingredient. It should be understood that the pharmaceutical composition according to the invention optionally comprises a pharmaceutical carrier, and that the pharmaceutical composition optionally

comprises further compounds, such as chemotherapeutic compounds, anti-inflammatory compounds, antiviral compounds and/or immuno-modulating compounds.

The oligomeric compound comprised in this invention can be employed in a variety of
5 pharmaceutically acceptable salts. As used herein, the term refers to salts that retain the desired biological activity of the herein-identified compounds and exhibit minimal undesired toxicological effects. Non-limiting examples of such salts can be formed with organic amino acid and base addition salts formed with metal cations such as zinc, calcium, bismuth, barium, magnesium, aluminum, copper, cobalt, nickel, cadmium,
10 sodium, potassium, and the like, or with a cation formed from ammonia, *N,N*-dibenzylethylene-diamine, *D*-glucosamine, tetraethylammonium, or ethylenediamine.

In one embodiment of the invention the oligomeric compound may be in the form of a pro-drug. Oligonucleotides are by virtue negatively charged ions. Due to the lipophilic nature of
15 cell membranes the cellular uptake of oligonucleotides are reduced compared to neutral or lipophilic equivalents. This polarity "hindrance" can be avoided by using the pro-drug approach (see e.g. Crooke, R. M. (1998) in Crooke, S. T. *Antisense research and Application*. Springer-Verlag, Berlin, Germany, vol. 131, pp. 103-140). In this approach the oligonucleotides are prepared in a protected manner so that the oligo is neutral when it
20 is administered. These protection groups are designed in such a way that they can be removed when the oligo is taken up by the cells. Examples of such protection groups are *S*-acetylthioethyl (SATE) or *S*-pivaloylthioethyl (*t*-butyl-SATE). These protection groups are nuclease resistant and are selectively removed intracellularly.

25 Pharmaceutically acceptable binding agents and adjuvants may comprise part of the formulated drug. Capsules, tablets and pills etc. may contain for example the following compounds: microcrystalline cellulose, gum or gelatin as binders; starch or lactose as excipients; stearates as lubricants; various sweetening or flavouring agents. For capsules the dosage unit may contain a liquid carrier like fatty oils. Likewise coatings of sugar or
30 enteric agents may be part of the dosage unit. The oligonucleotide formulations may also be emulsions of the active pharmaceutical ingredients and a lipid forming a micellular emulsion. A compound of the invention may be mixed with any material that do not impair the desired action, or with material that supplement the desired action. These could include other drugs including other nucleotide compounds. For parenteral, subcutaneous,
35 intradermal or topical administration the formulation may include a sterile diluent, buffers, regulators of tonicity and antibacterials. The active compound may be prepared with carriers that protect against degradation or immediate elimination from the body, including implants or microcapsules with controlled release properties. For intravenous administration the preferred carriers are physiological saline or phosphate buffered saline.

Preferably, an oligomeric compound is included in a unit formulation such as in a pharmaceutically acceptable carrier or diluent in an amount sufficient to deliver to a patient a therapeutically effective amount without causing serious side effects in the treated patient.

5

The pharmaceutical compositions of the present invention may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be (a) oral (b) pulmonary, e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, (c) 10 topical including epidermal, transdermal, ophthalmic and to mucous membranes including vaginal and rectal delivery; or (d) parenteral including intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. In one embodiment the pharmaceutical composition is administered IV, IP, orally, topically or as a bolus injection or administered 15 directly in to the target organ. Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, sprays, suppositories, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. Coated condoms, gloves and the like may also be useful. Preferred topical formulations include 20 those in which the compounds of the invention are in admixture with a topical delivery agent such as lipids, liposomes, fatty acids, fatty acid esters, steroids, chelating agents and surfactants. Compositions and formulations for oral administration include but is not restricted to powders or granules, microparticulates, nanoparticulates, suspensions or solutions in water or non-aqueous media, capsules, gel capsules, sachets, tablets or 25 minitables. Compositions and formulations for parenteral, intrathecal or intraventricular administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives such as, but not limited to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients.

30 Pharmaceutical compositions of the present invention include, but are not limited to, solutions, emulsions, and liposome-containing formulations. These compositions may be generated from a variety of components that include, but are not limited to, preformed liquids, self-emulsifying solids and self-emulsifying semisolids. Delivery of drug to tumour tissue may be enhanced by carrier-mediated delivery including, but not limited to, cationic 35 liposomes, cyclodextrins, porphyrin derivatives, branched chain dendrimers, polyethyleneimine polymers, nanoparticles and microspheres (Dass CR. J Pharm Pharmacol 2002; 54(1):3-27). The pharmaceutical formulations of the present invention, which may conveniently be presented in unit dosage form, may be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of

bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product. The compositions of the present invention may be formulated into any of many possible dosage forms such as, but not limited to, tablets, capsules, gel capsules, liquid syrups, soft gels and suppositories. The compositions of the present invention may also be formulated as suspensions in aqueous, non-aqueous or mixed media. Aqueous suspensions may further contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethyl-cellulose, sorbitol and/or dextran. The suspension may also contain stabilizers. The compounds of the invention may also be conjugated to active drug substances, for example, aspirin, ibuprofen, a sulfa drug, an antidiabetic, an antibacterial or an antibiotic.

In another embodiment, compositions of the invention may contain one or more siRNA compounds, targeted to a first nucleic acid and one or more additional siRNA compounds targeted to a second nucleic acid target. Two or more combined compounds may be used together or sequentially.

The compounds disclosed herein are useful for a number of therapeutic applications as indicated above. In general, therapeutic methods of the invention include administration of a therapeutically effective amount of a siRNA to a mammal, particularly a human. In a certain embodiment, the present invention provides pharmaceutical compositions containing (a) one or more compounds of the invention, and (b) one or more chemotherapeutic agents. When used with the compounds of the invention, such chemotherapeutic agents may be used individually, sequentially, or in combination with one or more other such chemotherapeutic agents or in combination with radiotherapy. All chemotherapeutic agents known to a person skilled in the art are here incorporated as combination treatments with compound according to the invention. Other active agents, such as anti-inflammatory drugs, including but not limited to nonsteroidal anti-inflammatory drugs and corticosteroids, antiviral drugs, and immuno-modulating drugs may also be combined in compositions of the invention. Two or more combined compounds may be used together or sequentially.

Cancer

In an even further aspect the present invention relates to the use of a compound according to the invention for the manufacture of a medicament for the treatment of cancer. In another aspect the present invention concerns a method for treatment of, or prophylaxis against, cancer, said method comprising administering a compound of the invention or a pharmaceutical composition of the invention to a patient in need thereof.

Such cancers may include lymphoreticular neoplasia, lymphoblastic leukemia, brain tumors, gastric tumors, plasmacytomas, multiple myeloma, leukemia, connective tissue tumors, lymphomas, and solid tumors.

5

In the use of a compound of the invention for the manufacture of a medicament for the treatment of cancer, said cancer may suitably be in the form of a solid tumor. Analogously, in the method for treating cancer disclosed herein said cancer may suitably be in the form of a solid tumor.

10

Furthermore, said cancer is also suitably a carcinoma. The carcinoma is typically selected from the group consisting of malignant melanoma, basal cell carcinoma, ovarian carcinoma, breast carcinoma, non-small cell lung cancer, renal cell carcinoma, bladder carcinoma, recurrent superficial bladder cancer, stomach carcinoma, prostatic carcinoma, pancreatic carcinoma, lung carcinoma, cervical carcinoma, cervical dysplasia, laryngeal papillomatosis, colon carcinoma, colorectal carcinoma and carcinoid tumors. More typically, said carcinoma is selected from the group consisting of malignant melanoma, non-small cell lung cancer, breast carcinoma, colon carcinoma and renal cell carcinoma. The malignant melanoma is typically selected from the group consisting of superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma, acral melanoma, amelanotic melanoma and desmoplastic melanoma.

20

Alternatively, the cancer may suitably be a sarcoma. The sarcoma is typically in the form selected from the group consisting of osteosarcoma, Ewing's sarcoma, chondrosarcoma, malignant fibrous histiocyoma, fibrosarcoma and Kaposi's sarcoma.

25

Alternatively, the cancer may suitably be a glioma.

A further embodiment is directed to the use of a compound according to the invention for the manufacture of a medicament for the treatment of cancer, wherein said medicament further comprises a chemotherapeutic agent selected from the group consisting of adrenocorticosteroids, such as prednisone, dexamethasone or decadron; altretamine (hexalen, hexamethylmelamine (HMM)); amifostine (ethyol); aminoglutethimide (cytadren); amsacrine (M-AMSA); anastrozole (arimidex); androgens, such as testosterone; asparaginase (elspar); bacillus calmette-gurin; bicalutamide (casodex); bleomycin (blenoxane); busulfan (myleran); carboplatin (paraplatin); carmustine (BCNU, BiCNU); chlorambucil (leukeran); chlorodeoxyadenosine (2-CDA, cladribine, leustatin); cisplatin (platinol); cytosine arabinoside (cytarabine); dacarbazine (DTIC); dactinomycin (actinomycin-D, cosmegen); daunorubicin (cerubidine); docetaxel (taxotere); doxorubicin

30

35

(adriomycin); epirubicin; estramustine (emcyt); estrogens, such as diethylstilbestrol (DES); etoposide (VP-16, VePesid, etopophos); fludarabine (fludara); flutamide (eulexin); 5-FUDR (floxuridine); 5-fluorouracil (5-FU); gemcitabine (gemzar); goserelin (zodalex); herceptin (trastuzumab); hydroxyurea (hydrea); idarubicin (idamycin); ifosfamide; IL-2
 5 (proleukin, aldesleukin); interferon alpha (intron A, roferon A); irinotecan (camptosar); leuprolide (lupron); levamisole (ergamisole); lomustine (CCNU); mechlorathamine (mustargen, nitrogen mustard); melphalan (alkeran); mercaptopurine (purinethol, 6-MP); methotrexate (mexate); mitomycin-C (mutamucin); mitoxantrone (novantrone); octreotide (sandostatin); pentostatin (2-deoxycoformycin, nipent); plicamycin
 10 (mithramycin, mithracin); prorocarbazine (matulane); streptozocin; tamoxifen (nolvadex); taxol (paclitaxel); teniposide (vumon, VM-26); thiotepa; topotecan (hycamtin); tretinoin (vesanoid, all-trans retinoic acid); vinblastine (valban); vincristine (oncovin) and vinorelbine (navelbine). Suitably, the further chemotherapeutic agent is selected from taxanes such as Taxol, Paclitaxel or Docetaxel.

15

Similarly, the invention is further directed to the use of a compound according to the invention for the manufacture of a medicament for the treatment of cancer, wherein said treatment further comprises the administration of a further chemotherapeutic agent selected from the group consisting of adrenocorticosteroids, such as prednisone,

20 dexamethasone or decadron; altretamine (hexalen, hexamethylmelamine (HMM)); amifostine (ethyol); aminoglutethimide (cytadren); amsacrine (M-AMSA); anastrozole (arimidex); androgens, such as testosterone; asparaginase (elspar); bacillus calmette-gurin; bicalutamide (casodex); bleomycin (blenoxane); busulfan (myleran); carboplatin (paraplatin); carmustine (BCNU, BiCNU); chlorambucil (leukeran); chlorodeoxyadenosine
 25 (2-CDA, cladribine, leustatin); cisplatin (platinol); cytosine arabinoside (cytarabine); dacarbazine (DTIC); dactinomycin (actinomycin-D, cosmegen); daunorubicin (cerubidine); docetaxel (taxotere); doxorubicin (adriomycin); epirubicin; estramustine (emcyt); estrogens, such as diethylstilbestrol (DES); etoposide (VP-16, VePesid, etopophos); fludarabine (fludara); flutamide (eulexin); 5-FUDR (floxuridine); 5-fluorouracil (5-FU);
 30 gemcitabine (gemzar); goserelin (zodalex); herceptin (trastuzumab); hydroxyurea (hydrea); idarubicin (idamycin); ifosfamide; IL-2 (proleukin, aldesleukin); interferon alpha (intron A, roferon A); irinotecan (camptosar); leuprolide (lupron); levamisole (ergamisole); lomustine (CCNU); mechlorathamine (mustargen, nitrogen mustard); melphalan (alkeran); mercaptopurine (purinethol, 6-MP); methotrexate (mexate); mitomycin-C (mutamucin);
 35 mitoxantrone (novantrone); octreotide (sandostatin); pentostatin (2-deoxycoformycin, nipent); plicamycin (mithramycin, mithracin); prorocarbazine (matulane); streptozocin; tamoxifen (nolvadex); taxol (paclitaxel); teniposide (vumon, VM-26); thiotepa; topotecan (hycamtin); tretinoin (vesanoid, all-trans retinoic acid); vinblastine (valban); vincristine (oncovin) and vinorelbine (navelbine). Suitably, said treatment further comprises the

administration of a further chemotherapeutic agent selected from taxanes, such as Taxol, Paclitaxel or Docetaxel.

Alternatively stated, the invention is furthermore directed to a method for treating cancer,
5 said method comprising administering a compound of the invention or a pharmaceutical composition according to the invention to a patient in need thereof and further comprising the administration of a further chemotherapeutic agent. Said further administration may be such that the further chemotherapeutic agent is conjugated to the compound of the invention, is present in the pharmaceutical composition, or is administered in a separate
10 formulation.

Infectious Diseases

In a particular interesting embodiment of the invention, siLNA compounds according to the invention are used for targeting Severe Acute Respiratory Syndrome (SARS), which first
15 appeared in China in November 2002. According to the WHO over 8,000 people have been infected world-wide, resulting in over 900 deaths. A previously unknown coronavirus has been identified as the causative agent for the SARS epidemic (Drosten C et al. N Engl J Med 2003,348,1967-76; and Fouchier RA et al. Nature 2003,423,240). Identification of the SARS-CoV was followed by rapid sequencing of the viral genome of multiple isolates (Ruan
20 et al. Lancet 2003,361,1779-85; Rota PA et al. Science 2003,300,1394-9; and Marra MA et al. Science 2003,300,399-404). This sequence information immediately made possible the development of SARS antivirals by nucleic acid-based knock-down techniques such as siRNA. The nucleotide sequence encoding the SARS-CoV RNA-dependent RNA polymerase (Pol) is highly conserved throughout the coronavirus family. The Pol gene product is
25 translated from the genomic RNA as a part of a polyprotein, and uses the genomic RNA as a template to synthesize negative-stranded RNA and subsequently sub-genomic mRNA. The Pol protein is thus expressed early in the viral life cycle and is crucial to viral replication (see Fig. 10).

30 Accordingly, in a further another aspect the present invention relates the use of a compound according to the invention for the manufacture of a medicament for the treatment of Severe Acute Respiratory Syndrome (SARS), as well as to a method for treating Severe Acute Respiratory Syndrome (SARS), said method comprising administering a compound according to the invention or a pharmaceutical composition
35 according to the invention to a patient in need thereof.

It is contemplated that the compounds of the invention may be broadly applicable to a broad range of infectious diseases, such as diphtheria, tetanus, pertussis, polio, hepatitis B, hemophilus influenza, measles, mumps, and rubella.

Accordingly, in yet another aspect the present invention relates the use of a compound according to the invention for the manufacture of a medicament for the treatment of an infectious disease, as well as to a method for treating an infectious disease, said method
5 comprising administering a compound according to the invention or a pharmaceutical composition according to the invention to a patient in need thereof.

Inflammatory Diseases

The inflammatory response is an essential mechanism of defense of the organism against
10 the attack of infectious agents, and it is also implicated in the pathogenesis of many acute and chronic diseases, including autoimmune disorders. In spite of being needed to fight pathogens, the effects of an inflammatory burst can be devastating. It is therefore often necessary to restrict the symptomatology of inflammation with the use of anti-inflammatory drugs. Inflammation is a complex process normally triggered by tissue injury
15 that includes activation of a large array of enzymes, the increase in vascular permeability and extravasation of blood fluids, cell migration and release of chemical mediators, all aimed to both destroy and repair the injured tissue.

In yet another aspect, the present invention relates to the use of a compound according to
20 the invention for the manufacture of a medicament for the treatment of an inflammatory disease, as well as to a method for treating an inflammatory disease, said method comprising administering a compound according to the invention or a pharmaceutical composition according to the invention to a patient in need thereof.

25 In one preferred embodiment of the invention, the inflammatory disease is a rheumatic disease and/or a connective tissue diseases, such as rheumatoid arthritis, systemic lupus erythematosus (SLE) or Lupus, scleroderma, polymyositis, inflammatory bowel disease, dermatomyositis, ulcerative colitis, Crohn's disease, vasculitis, psoriatic arthritis, exfoliative psoriatic dermatitis, pemphigus vulgaris and Sjorgren's syndrome, in particular
30 inflammatory bowel disease and Crohn's disease.

Alternatively, the inflammatory disease may be a non-rheumatic inflammation, like bursitis, synovitis, capsulitis, tendinitis and/or other inflammatory lesions of traumatic and/or sportive origin.

35

Other Uses

The siRNA compounds of the present invention can be utilized for as research reagents for diagnostics, therapeutics and prophylaxis. In research, the siRNA may be used to specifically inhibit the synthesis of target genes in cells and experimental animals thereby

facilitating functional analysis of the target or an appraisal of its usefulness as a target for therapeutic intervention. In diagnostics the siRNA oligonucleotides may be used to detect and quantitate target expression in cell and tissues by Northern blotting, in-situ hybridisation or similar techniques. For therapeutics, an animal or a human, suspected of having a disease or disorder, which can be treated by modulating the expression of target is treated by administering the siRNA compounds in accordance with this invention. Further provided are methods of treating an animal particular mouse and rat and treating a human, suspected of having or being prone to a disease or condition, associated with expression of target by administering a therapeutically or prophylactically effective amount of one or more of the siRNA compounds or compositions of the invention.

The invention is further illustrated in a non-limiting manner by the following examples.

EXAMPLES

15

Abbreviations

DMT:	Dimethoxytrityl
DCI:	4,5-Dicyanoimidazole
DMAP:	4-Dimethylaminopyridine
20 DCM:	Dichloromethane
DMF:	Dimethylformamide
THF:	Tetrahydrofuran
DIEA:	<i>N,N</i> -diisopropylethylamine
PyBOP:	Benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium
25 hexafluorophosphate	
Bz:	Benzoyl
Ibu:	Isobutyryl
Beaucage:	3H-1,2-Benzodithiole-3-one-1,1-dioxide
GL3+:	5'-cuuacgcugaguacuucga _d t _d t-3',
30 GL3-:	5'-ucgaaguacucagcguaag _d t _d t-3'
NPY+:	5'-ugagagaaagcacagaaaa _d t _d t-3'
NPY-:	5'-uuuucugugcuucucuca _d t _d t-3'
RL+:	5'-aucugaagaaggagaaaa _d t _d t-3'
RL-:	5'-uuuuucuccuucucagau _d t _d t-3'
35 Small letters without prefix:	RNA monomer
Small letters with "d" prefix:	DNA monomer

Example 1: Monomer Synthesis

The preparation of LNA monomers is described in great detail in the references Koshkin et al., J. Org. Chem., 2001,66,8504-8512, and Pedersen et al., Synthesis, 2002,6,802-809 as well as in references given therein. Where the Z and Z* protection groups were oxy-
5 N,N-diisopropyl-O-(2-cyanoethyl)phosphoramidite and dimethoxytrityloxy such compounds were synthesised as described in WO 03/095467; Pedersen et al., Synthesis 6, 802-808, 2002; Sørensen et al., J. Am. Chem. Soc., 124, 2164-2176, 2002; Singh et al., J. Org. Chem. 63, 6078-6079, 1998; and Rosenbohm et al., Org. Biomol. Chem. 1, 655-663, 2003. All cytosine-containing monomers were replaced with 5-methyl-cytosine monomers
10 for all couplings. All LNA monomers used were beta-D-oxy LNA (compound **3A**).

Example 2: Oligonucleotide Synthesis

All syntheses were carried out in 1 µmole scale on a MOSS Expedite instrument platform. The synthesis procedures were carried out essentially as described in the instrument
15 manual.

Preparation of LNA Succinyl Hemiesther

5'-O-DMT-3''hydroxy-LNA monomer (500 mg), succinic anhydride (1.2 eq.) and DMAP (1.2 eq.) were dissolved in DCM (35 ml). The reaction mixture was stirred at room temperature
20 overnight. After extraction with NaH₂PO₄, 0.1 M, pH 5.5 (2x), and brine (1x), the organic layer was further dried with anhydrous Na₂SO₄, filtered, and evaporated. The hemiester derivative was obtained in a 95% yield and was used without any further purification.

Preparation of LNA-CPG (Controlled Pore Glass)

25 The above-prepared hemiester derivative (90 µmole) was dissolved in a minimum amount of DMF. DIEA and pyBOP (90 µmole) were added and mixed together for 1 min. This pre-activated mixture was combined with LCAA-CPG (500 Å, 80-120 mesh size, 300 mg) in a manual synthesiser and stirred. After 1.5 h stirring at room temperature, the support was filtered off and washed with DMF, DCM and MeOH. After drying the loading was determined
30 to be 57 µmol/g (see Tom Brown, Dorcas J.S.Brown. Modern machine-aided methods of oligodeoxyribonucleotide synthesis. In: F.Eckstein, editor. Oligonucleotides and Analogues A Practical Approach. Oxford: IRL Press, 1991: 13-14).

Phosphorothioate Cycles

35 5'-O-DMT (A(bz), C(bz), G(ibu) or T) linked to CPG were deprotected using a solution of 3% trichloroacetic acid (v/v) in dichloromethane. The CPG was washed with acetonitrile. Coupling of phosphoramidites (A(bz), G(ibu), 5-methyl-C(bz)) or T-β-cyanoethyl-phosphoramidite) was performed by using 0.08 M solution of the 5'-O-DMT-protected

amidite in acetonitrile and activation was done by using DCI (4,5-dicyanoimidazole) in acetonitrile (0.25 M). The coupling reaction was carried out for 2 min. Thiolation was carried out by using Beaucage reagent (0.05 M in acetonitrile) and was allowed to react for 3 min. The support was thoroughly washed with acetonitrile and the subsequent capping

5 was carried out by using standard solutions (CAP A) and (CAP B) to cap unreacted 5' hydroxyl groups. The capping step was then repeated and the cycle was concluded by acetonitrile washing.

LNA Unit Cycles

- 10 5'-O-DMT (A(bz), C(bz), G(ibu) or T) linked to CPG was deprotected by using the same procedure as described above. Coupling was performed by using 5'-O-DMT-A(bz), C(bz), G(ibu) or T- β -cyanoethylphosphoramidite (0.1 M in acetonitrile) and activation was done by DCI (0.25 M in acetonitrile). The coupling reaction was carried out for 7 minutes. Capping was done by using standard solutions (CAP A) and (CAP B) for 30 sec. The
- 15 phosphite triester was oxidized to the more stable phosphate triester by using a standard solution of I₂ and pyridine in THF for 30 sec. The support was washed with acetonitrile and the capping step was repeated. The cycle was concluded by thorough acetonitrile wash.

Cleavage and Deprotection

- 20 The oligonucleotides were cleaved from the support and the β -cyanoethyl protecting group removed by treating the support with 35% NH₄OH for 1 h at room temperature. The support was filtered off and the base protecting groups were removed by raising the temperature to 65°C for 4 hours. Ammonia was then removed by evaporation.

25 Purification

The oligos were either purified by reversed-phase-HPLC (RP-HPLC) or by anion exchange chromatography (AIE):

RP-HPLC:

- 30 Column: VYDAC™, Cat. No. 218TP1010 (vydac)
 Flow rate: 3 ml/min
 Buffer: A (0.1 M ammonium acetate, pH 7.6)
 B (acetonitrile)

Gradient:

- 35 Time 0 10 18 22 23 28
 B% 0 5 30 100 100 0

AIE:

Column: Resource™ 15Q (amersham pharmacia biotech)

Flow rate: 1.2 ml/min

Buffer: A (0.1 M NaOH)

5 B (0.1 M NaOH, 2.0 M NaCl)

Gradient:

Time 0 1 27 28 32 33

B% 0 25 55 100 100 0

10

Tm Measurement

Melting curves were recorded on a Perkin Elmer UV/VIS spectrophotometer lambda 40 attached to a PTP-6 Peltier System. Oligonucleotides were dissolved in salt buffer (10 mM phosphate buffer, 100 mM NaCl, 0.1 mM EDTA, pH 7.0) at a concentration of 1.5 µM and using 1 cm path-length cells. Samples were denatured at 95°C for 3 min and slowly cooled to 20°C prior to measurements. Melting curves were recorded at 260 nm using a heating rate of 1°C/min, a slit of 2 nm and a response of 0.2 sec. Tm values were obtained from the maximum of the first derivative of the melting curves.

15

20 **Example 3: Synthesis of LNA/RNA Oligonucleotides**

Synthesis

LNA/RNA oligonucleotides were synthesized DMT-off on a 1.0 µmole scale using an automated nucleic acid synthesiser (MOSS Expedite 8909) and using standard reagents. 1H-tetrazole or 5-ethylthio-1H-tetrazole were used as activators. The LNA A^{Bz}, G^{iBu} and T phosphoramidite concentration was 0.1 M in anhydrous acetonitrile. The MeC^{Bz} was dissolved in 15 % THF in acetonitrile. The coupling time for all monomer couplings was 600 secs. The RNA phosphoramidites (Glen Research, Sterling, Virginia) were N-acetyl and 2'-O-triisopropylsilyloxymethyl (TOM) protected. The monomer concentration was 0.1 M (anhydrous acetonitrile) and the coupling time was 900 secs. The oxidation time was set to be 50 sec. The solid support was DMT-LNA-CPG (1000 Å, 30-40 µmole/g).

30

Work-up and Purification

Cleavage from the resin and nucleobase/phosphate deprotection was carried out in a sterile tube by treatment with 1.5 ml of a methylamine solution (1:1, 33% methylamine in ethanol:40% methylamine in water) at 35°C for 6 h or left overnight. The tube was centrifuged and the methylamine solution was transferred to second sterile tube. The methylamine solution was evaporated in a vacuum centrifuge. To remove the 2'-O-protection groups the residue was dissolved in 1.0 ml 1.0 M TBAF in THF and heated to

35

55°C for 15 min. and left at 35°C overnight. The THF was evaporated in a vacuum centrifuge leaving a light yellow gum, which was neutralised with approx. 600 µl (total sample volume: 1.0 ml) of RNase-free 1.0 M Tris-buffer (pH 7). The mixture was homogenised by shaking and heating to 65°C for 3 min. Desalting of the oligonucleotides was performed on NAP-10 columns (Amersham Biosciences, see below). The filtrate from step 4 (see below) was collected and analysed by MALDI-TOF and gel electrophoresis (16% sequencing acrylamide gel (1 mm), 0.9% TBE [Tris: 89 mM, Boric acid: 89 mM, EDTA: 2 mM, pH 8.3] buffer, ran for 2 h at 20 W as the limiting parameter. The gel was stained in CyberGold (Molecular Probes, 1:10000 in 0.9xTBE) for 30 min followed by scanning in a Bio-Rad FX Imager). The concentration of the oligonucleotide was measured by UV-spectrometry at 260 nm.

Scheme A, Desalting on NAP-10 columns:

Step	Reagent	Operation	Volume	Remarks
1	-	Empty storage buffer	-	Discard
2	H ₂ O (RNase-free)	Wash	2 x full volume	Discard
3	Oligo in buffer (RNase-free)	Load	1.0 ml	Discard
4	H ₂ O (RNase-free)	Elution	1.5 ml	Collect – Contains oligo
5	H ₂ O (RNase-free)	"Elution"	0.5 ml	Collect – Contains salt + small amount of oligo

15

As will be appreciated by the skilled person, the most important issues in the synthesis of the LNA/RNA oligos as compared to standard procedures are that i) extended coupling times are necessary to achieve good coupling efficiency, and ii) the oxidation time has to be extended to minimise the formation of deletion fragments. Furthermore, coupling of 2'-O-TOM protected phosphoramidites were superior to 2'-O-TBDMS. Taking this into account, the crude oligonucleotides were of such quality that further purification could be avoided. MS analysis should be carried out after the TOM-groups are removed.

Example 4: Improved Stability of siLNA as Compared to siRNA

25 The improved stability of siLNA as compared to siRNA is shown in Fig. 2. Both slightly- and more heavily-modified siRNA exhibited improved stability. Stability was evaluated in 10%

foetal bovine serum diluted in a physiological saline solution. The siRNA and siLNA were incubated in the serum at 37°C. Samples were withdrawn at different time points and analysed on 15% polyacrylamide TBE gels and stained with SYBR-gold (Molecular probes). Bands were quantified and plotted in a graph. For the unmodified siRNA compound an accumulation of an intermediate band can be seen (inbetween dsRNA and ssRNA) that has been identified to be a doublestranded 19-mer, i.e. siRNA with degraded 3' overhangs. This was not observed for the corresponding siLNAs.

Example 5: Test of Design of siLNA in Mammalian Reporter System

- 10 The efficacy of different siLNA designs and combinations were first assessed in a luciferase reported system in mammalian cell culture. The oligonucleotides used are shown in Table 1. Sense and the corresponding antisense oligonucleotides were hybridised to generate double strands, i.e. siRNA or siLNA.
- 15 The cells used were the human embryonal kidney (HEK) 293 cell lines. HEK 293 cells were maintained in DMEM supplemented with 10% foetal bovine serum, penicillin, streptomycin and glutamine (Invitrogen, Paisely, UK). The plasmids used were pGL3-Control coding for firefly luciferase under the control of the SV40 promoter and enhancer and pRL-TK coding for *Renilla* luciferase under the control of HSV-TK promoter (Promega, Madison, WI, USA).
- 20

Transfection

- One day before transfection cells were seeded in 500 µl medium in 24-well plates in order to adhere and reach a confluency of 70 to 90% at the time of transfection. Cells were seeded in the medium without antibiotics and changed to 500 µl Opti-MEM I just before adding the transfection mix to the cells. A standard co-transfection mix was prepared for triplicate wells by separately adding 510 ng pGL3-Control, 51 ng pRL-TK and 340 ng siRNA to 150 µl Opti-MEM I (Invitrogen) and 3 µl LipofectAMINE 2000 (Invitrogen) to another 150 µl Opti-MEM I. The two solutions were mixed and incubated at room temperature for 20-30 minutes before adding to the cells. 100 µl of the transfection mix was added to each of the three wells. The final volume of medium plus transfection mix was 600 µl. The siLNA or siRNA concentration corresponded to about 13 nM. Cells were incubated with the transfection mix for 4 hours and the medium was then changed with fully supplemented DMEM.
- 25
- 30

35

Dual-Luciferase Reporter Assay (Promega)

Cells were harvested in passive lysis buffer and assayed according to the protocol (Promega) using a NovoSTAR 96-well format luminometer with substrate dispenser (BMG Labtechnologies, Offenburg, Germany). 10 µl sample was applied in each well of a 96 well

plate and 50 µl Luciferase Assay Reagent II (substrate for firefly luciferase) was added to a well by the luminometer and measured. Then, 50 µl Stop and Glow (stop solution for firefly luciferase and substrate for *Renilla* luciferase) was added and measured. The average of the luciferase activities measured for 10 sec. was used to calculate ratios between firefly
5 and *Renilla* luciferase or the opposite.

Example 6: *In vitro* model: Assessment off Efficacy on an Endogenous Target

The cells used were the rat adrenal pheochromocytoma, PC12 cell lines. PC12 were maintained in DMEM supplemented with 10% horse serum, 5% foetal bovine serum,
10 penicillin, streptomycine and glutamine. The SiLNA or siRNA transfection protocol for endogenous genes (like NPY in PC12 cells) follows the same procedure as described above but without luciferase plasmids and only adding siRNA targeting NPY (since the NPY gene is endogenously expressed in PC12 cells). Final siLNA or siRNA concentrations ranged from 1 to 100 nM. Cells were usually harvested 24 to 48 hours post transfection and mRNA was
15 extracted. mRNA levels were measured with Real-Time PCR. The down-regulation of the NPY target in PC12 is shown in Fig. 3.

Example 7: *In vitro* model: Analysis of Inhibition of Target

20 Expression by Real-time PCR

SiLNA or siRNA gene silencing of a target can be assayed in a variety of ways known in the art. For example, target mRNA levels can be quantified by, e.g., Northern blot analysis, competitive polymetargete chain reaction (PCR), or real-time PCR. Real-time quantitative PCR is presently preferred. RNA analysis can be performed on total cellular RNA or mRNA.
25 Methods of RNA isolation and RNA analysis, such as Northern blot analysis, is routine in the art and is taught in, for example, Current Protocols in Molecular Biology, John Wiley and Sons.

Cells were harvested and mRNA was extracted. Standard real-time PCR protocols were
30 used to amplify target genes from mRNA with gene specific primers along with a primer pair towards a housekeeping gene as internal control (such as Cyclophilin). Down-regulation was expressed as a ratio of amount target mRNA to amount control mRNA. Real-time quantitative (PCR) can be conveniently accomplished using the commercially available iQ Multi-Color Real Time PCR Detection System, available from BioRAD.

35

Example 8: *In vitro* analysis: SiRNA Inhibition of Reporter Target Expression by siLNA Oligonucleotides

LNA monomers could be used to modify both ends of the sense strand in siRNA with a maintained effect as compared to siRNA (>90 % inhibition of Firefly Luciferase expression

compared to untreated samples). The antisense strand could also be modified in the 3' end without loss of efficiency while a modification in the 5' end of the antisense strand reduced the effect to 25-50% inhibition. By exchanging all uracil-containing residues to LNA thymines in the sense strand reduced the effect to 80% inhibition. A similar modification of the antisense strand abolished the effect (Fig. 4). Phosphorylation of the 5' end of the siLNA antisense strand did not improve the reduction (20-30% reduction, data not shown). Similar experiments targeting Renilla Luciferase showed that both ends of the sense strand could be modified with LNA monomers while the antisense strand tolerates 3' end LNA monomer modification (95% inhibition in all cases), but showed less inhibition with both a 3' and a 5' end LNA modification. Still up to 75% inhibition was observed (Fig. 5). Stability of LNA/RNA was measured on all RNA uracil to LNA thymidine oligo (2189) in 100% rat serum, where the stability was similar to naked DNA oligos. An unmodified RNA single strand (GL3-) and unmodified double strand (GL3+/-) were degraded already at time point zero (Fig. 6).

15

Example 9: *In vitro* analysis: siRNA Inhibition of Endogenous Target by siLNA

Inhibition of Cytotoxicity

Cells were transfected with 85 nM of the respective siRNA or siLNA (SARS 1-4, see Fig. 7) or with control siRNA targeting the firefly luciferase gene (Luc) or the rat neuropeptide Y (NPY) gene. Mock-transfected cells were treated with Lipofectamine 2000 only and used as positive control. Uninfected cells were included as negative control. Transfected cells were infected with either 60,000, 6,000 or 600 TCID₅₀ of SARS-CoV. After 50 hours of infection, the CPE and the cytotoxicity was measured. There was a marked difference in CPE between the cells treated with the most effective siRNA, SARS 1, as compared to mock-transfected cells (Fig. 8). The cytotoxicity was determined as percent LDH release from treated cells as compared to mock-transfected control cells. The percent inhibition of cytotoxicity was calculated as 100 – percent cytotoxicity in the siRNA treated sample. The four Pol-specific siRNA and siLNA had various effects on cytotoxicity (Fig. 9). The most effective siRNA and siLNA were the ones targeting the SARS 1 site, which reduced cytotoxicity and with up to 65% at 600 TCID₅₀. The SARS 3 site was medium efficient using siRNA at all three viral doses. However SARS 3 became an equally efficient site as SARS 1 by using siLNA, also at all three viral doses. The sites SARS 2 and SARS 4 did not show any effect by siRNA or siLNA at any viral dose. The data represent mean and standard deviation determined by three independent experiments in quadruplicate.

35

Virus and Cells

Vero cells were used for all cellular experiments. Cells were cultivated in phenol red-free Eagle's MEM containing 5% FCS and 1% PEST at 37°C and 5% CO₂. The Frankfurt 1 isolate

(GenBank accession number AY291315, kindly provided by Dr. H. W. Doerr) was grown to high titers on Vero cells. Supernatants from two T225 cell culture flasks were pooled and frozen at -80°C in 1 ml vials and constituted the viral stock. The stock virus was identified as SARS-CoV by diagnostic reverse transcriptase PCR using the BNIoutS2 and BNIoutAs¹¹ primers and the Cor-p-F2 and Cor-p-R1 primers². The virus stock was used in ten-fold dilutions or at a fixed dilution to infect Vero cells in 96 well cell culture plates. The virus stock was diluted 600,000 times (determined by the Reed-Muench method) to reach TCID₅₀ in 96 well cell culture plates.

- 10 The siRNA oligonucleotides were produced as described above. The sequence are shown in Fig. 7.

Transfections

Lipofectamine2000 (Invitrogen) was used to transect the cells with siRNA and siLNA.

- 15 Transfection efficiency was high and most cell were transfected. The transfection medium was changed to phenol red-free Eagle's MEM after four hours, and cells were grown overnight to form a confluent monolayer.

Cytopathogenicity and Cytotoxicity

- 20 The cytopathogenic effect (CPE) on infected cells was detected as cell rounding and detachment from the cell culture plate. The CPE was scored in a light microscope. The cytotoxicity was measured using a cytotoxicity detection kit (LDH) (Roche, Germany). Mock-transfected cells treated with lipofectamine2000 only were set as 100% cytotoxicity caused by the virus infection at each viral dilution. Uninfected cells were used to determine the background cytotoxicity. The percent cytotoxicity was determined as $[(\text{Abs}_{490} \text{ sample} - \text{background}) / (\text{Abs}_{490} \text{ mock-transfected controls} - \text{background})] \times 100$. The inhibition of cytotoxicity was calculated as $[(1 - (\text{Abs}_{490} \text{ sample} - \text{background}) / (\text{Abs}_{490} \text{ mock-transfected controls} - \text{background})) \times 100]$.

30 Example 10: Reduction of Off-Site Effects

Inhibition of SARS sense/antisense target in 3'UTR of firefly luciferase was performed at 1.6 nM siRNA/siLNA with the plasmids: pS3Xs (pGL3 with SARS sense target), pS3Xas (pGL3 with SARS antisense target), and pGL3 (without SARS target).

- 35 The SARS 3 target sequence was cloned in sense (sequence corresponding to the SARS mRNA) and antisense direction (complementary sequence to the SARS mRNA) in firefly luciferase 3' UTR, between the luciferase coding region and poly A in pGL3. pGL3 was cut with Xba I (between luc. stop codon and poly A) and a SARS S3 target sequence DNA oligo duplex with Xba I overhangs.

(SARS 3 target (SARS genomic position 14593) DNA oligo duplex with Xba I overhangs)
5'-ctagcaaaactgtcaaaccggtattttc-3' (sense, same as mRNA)
3'-gtttgacagtttgggccattaaaaggatc-5' (antisense, complementary to the mRNA)

5

Ligation of the oligo duplex resulted in two plasmid products with either sense or antisense target (pS3Xs: target in sense direction, pS3Xas: target in antisense direction). The two different plasmids were transfected into separate HEK293 cell cultures along with control plasmid pRL-TK and siRNA targeting SARS3 or siLNA targeting SARS3 (final concentration
10 1.6 nM), according to protocol described in Example 5. Cells were incubated for 24 hours, cells were harvested and luciferase activity measured as described in Example 5.

siLNA can inactivate the unwanted sense strand while maintaining full effect of the antisense strand. siRNA shows effect of both strands. SARS 3 target sequence was cloned
15 in both sense and antisense direction where after siLNA and siRNA were assayed for inhibitory effects on two the different plasmids.

siRNA shows down-regulation of both sense target (part from SARS mRNA sequence, ~90% reduction of luciferase activity) as well as the antisense target (complementary
20 sequence to the SARS mRNA) (~50% reduction). Hence both the sense and antisense strand in the siRNA have a down regulatory effect. However, siLNA SARS 3 shows equally good effect down-regulating the sense target (~90% reduction) while there is no activity on the antisense target (0% reduction). Hence the antisense strand in the siLNA maintains full effect while the effect of the unwanted sense strand is abolished. This means that
25 siLNA can minimize off-targets by the sense strand by inactivating it to the RNA interference machinery (Fig. 17).

Example 11: *In Vivo* Efficacy of siLNA

The purpose of this study was to test the *in vivo* efficacy of two anti eGFP siRNAs which
30 have been modified by incorporation of LNA monomers. The used compounds were 3029/3031 and 3030/3031.

In brief, female nude mice (NMRI nu/nu, Charles River Netherlands, Maastricht, The Netherlands) were injected with 15PC3 and Miapaca xenografts. The 15PC3 cells and
35 Miapaca cells express eGFP as described by Fluiter et al. (2002) Cancer Research 62, 2024-2028.

After two weeks of tumor growth the mice were subcutaneously fitted with Osmotic minipumps (Alzet 1007D, lot no. 10052-02 (7 day pumps) (Durect Corporation, Cupertino, CA)). These pumps were filled with either 3029/3031 or 3030/3031 to give a dosage of 0.5 mg/kg/day. The mice were treated for 5 days. At the 5th day the mice were sacrificed and the tumor fluorescence was imaged and measured using a LAS3000 luminescent image analyser (Fujifilm). The fluorescence was quantified using AIDA software (Raytest GmbH, Straubenhardt, Germany). After imaging the tumors were taken out and stored for protein analysis (western blot). The obtained results for 15PC3 are shown in Fig. 18. As can be seen the siRNA compounds had a significant effect on tumor growth. Similar results were obtained with the Miapaca xenograft model.

The siRNA was checked prior to implantation and after the experiment (leftover in the pump) using MALDI-tof analysis. The siRNA was purified by ion exchange on the purification plates from the Nucleave genotyping kit (Waters, Milford, MA, USA) and analyzed using Matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF) on a Biflex III MALDI (Brucker instruments, Leipzig, Germany). Data are shown in Fig. 20.

Table 1

No	Sequence (5'→3')	Conc. (μM)	Purity
2184	cuuacgcugaguacuucgaTT	440	~80%
2185	^{Me} CuuacgcugaguacuucgaTT	320	~70%
2186	ucgaaguacucagcguaagTT	380	~65%
2187	TcgaaguacucagcguaagTT	340	~60%
2187-phos	Phos-TcgaaguacucagcguaagTT	350	~80%
2188	^{Me} CTTcgcTagTacTTcgaTT	410	~50%
2189	TcgaagTacTcagcgTaagTT	390	~55%
2189-phos	Phos-TcgaagTacTcagcgTaagTT	330	~80%
2699-1	uuuuucuccuucuucagauTT	400	~80%
2700-1	aucugaagaaggagaaaaaTT	400	~80%
2701-1	TuuuucuccuucuucagauTT	360	~80%
2702-1	AucugaagaaggagaaaaaTT	430	~80%
2703-1	^{Me} CTTacgcTgagTacTTcgaTT	500	~80%

Capital letters: Beta-D-oxy LNA monomer

Small letters: RNA monomer

Phos: 5'-phosphate

^{Me}C: 5-methylcytosine

Table 2

No	Sequence (5'→3')
2780	^{Me} CTTA ^{Me} CG ^{Me} CTGAGTA ^{Me} CTT ^{Me} CGATT
2781	_d cT _d tA _d cG _d cT _d gA _d gT _d a ^{Me} C _d tT _d cG _d aTT
2782	_d cT _d t _d a ^{Me} C _d g _d cT _d g _d aG _d t _d a ^{Me} C _d t _d t ^{Me} C _d g _d aTT
2783	^{Me} CuuAcGcuGaGua ^{Me} Cuu ^{Me} CgaTT
2784	^{Me} C _d u _d uA _d cG _d c _d uG _d aG _d u _d a ^{Me} C _d u _d u ^{Me} C _d g _d aTT
2785	u ^{Me} CGAAGTA ^{Me} CT ^{Me} CAG ^{Me} CGTAAGTT
2786	u ^{Me} C _d gA _d aG _d tA _d cT _d cA _d g ^{Me} C _d gT _d aA _d gTT
2787	u ^{Me} C _d g _d aA _d g _d tA _d c _d t ^{Me} C _d a _d g ^{Me} C _d g _d tA _d a _d gTT
2788	ucGaaGua ^{Me} CucAgcGuAagTT
2789	u ^{Me} CgaaguacucagcguaagTT
2790	ucGaaguacucagcguaagTT
2792	ucgaAguacucagcguaagTT
2793	ucgaaGuacucagcguaagTT
2794	ucgaaguAcucagcguaagTT
2795	TgAgAgaaAgcAcAgaAaaTT
2796	TgagagaaagcacagaaaaTT
2797	TuuucugugcuuucucucaTT

Capital letters: Beta-D-oxy LNA monomer

Small letters without prefix: RNA monomer

Small letters with "d" prefix: DNA monomer

^{Me}C: 5-methylcytosine

Table 3

No	Sequence (5'→3')
2842-1	GgaugaggaaggcaauuuuTT
2843-1	uaaaauugccuuccucauccTT
2872-1	CugguacgauuucggugauTT
2845-1	aucaccgaaaucguaccagTT
2846-1	AcugucaaacccgguaauuTT
2847-1	aauuaccggguuugacaguTT
2848-1	GacaacuccuauucguaguTT
2849-1	acuacgaauaggaguugucTT
2862-1	UccagaacaaaccaaaccggTT
2863-1	AaacaugcagaaaaugcugTT
2864-1	ucgaagua ^{Me} CucagcguaagTT
2865-1	ucgaaguacTcagcguaagTT
2866-1	ucgaaguacu ^{Me} CagcguaagTT
2867-1	ucgaaguacucAgcguaagTT
2865-U	ucgaaguacAcagcguaagTT
3029	GcugaccugaaguucaucTT
3030	G ^{Me} CTgac ^{Me} CcuGaagTTcaucTT
3031	gaugaacuucagggucagcTT

Capital letters: Beta-D-oxy LNA monomer

Small letters without prefix: RNA monomer

^{Me}C: 5-methylcytosine

CLAIMS

1. A double-stranded compound comprising a sense strand and an antisense strand,
wherein each strand comprises 12-35 nucleotides and wherein said compound comprises
5 at least one locked nucleic acid (LNA) monomer.
2. The compound according to claim 1, wherein the sense strand comprises at least one
LNA monomer.
- 10 3. The compound according to claim 2, wherein the sense strand comprises 1-10 LNA
monomers.
4. The compound according to claim 2 or 3, wherein at least one LNA monomer is located
at the 5' end of the sense strand.
- 15 5. The compound according to claim 4, wherein at least two LNA monomers are located at
the 5' end of the sense strand
6. The compound according to any of the preceding claims, wherein at least one LNA
20 monomer is located at the 3' end of the sense strand.
7. The compound according to claim 6, wherein at least two LNA monomers are located at
the 3' end of the sense strand.
- 25 8. The compound according to any of the preceding claims, wherein the antisense strand
comprises at least one LNA monomer.
9. The compound according to claim 8, wherein the antisense strand comprises 1-10 LNA
monomers.
- 30 10. The compound according to claim 8 or 9, wherein at least one LNA monomer is located
at the 3' end of the antisense strand.
11. The compound according to claim 10, wherein at least two LNA monomers are located
35 at the 3' end of the antisense strand.
12. The compound according to claim 11, wherein at least three LNA monomers are
located at the 3' end of the antisense strand.

13. The compound according to any of the preceding claims, wherein no LNA monomer is located at the 5' end of the antisense strand.
14. The compound according to any of the preceding claims, wherein the sense strand
5 comprises at least one LNA and the antisense strand comprises at least one LNA monomer.
15. The compound according to claim 14, wherein the sense strand comprises 1-10 LNA monomers and the antisense strand comprises 1-10 LNA monomers.
- 10 16. The compound according to claim 14 or 15, wherein the sense strand comprises at least one LNA monomer at the 5' end and at least one LNA monomer at the 3' end, and wherein the antisense strand comprises at least one LNA monomer at the 3' end.
17. The compound according to claim 16, wherein the sense strand comprises at least one
15 LNA monomer at the 5' end and at least one LNA monomer at the 3' end, and wherein the antisense strand comprises at least two LNA monomers at the 3' end.
18. The compound according to claim 17, wherein the sense strand comprises at least two LNA monomers at the 5' end and at least two LNA monomers at the 3' end, and wherein
20 the antisense strand comprises at least two LNA monomers at the 3' end.
19. The compound according to claim 18, wherein the sense strand comprises at least two LNA monomers at the 5' end and at least two LNA monomers at the 3' end, and wherein the antisense strand comprises at least three LNA monomers at the 3' end.
25
20. The compound according to any of claims 14-19, wherein no LNA monomer is located at the 5' end of the antisense strand.
21. The compound according to any of the preceding claims, wherein the sense strand
30 comprises at least one LNA monomer in at least one of the positions 9-13 counted from the 5' end.
22. The compound according to claim 21, wherein the sense strand comprises a LNA monomer in position 10.
35
23. The compound according to claim 21 or 22, wherein the sense strand comprises a LNA monomer in position 11.

24. The compound according to any of claims 21-23, wherein the sense strand comprises a LNA monomer in position 12.

25. The compound according to any of the preceding claims, wherein each strand
5 comprises 17-25 nucleotides.

26. The compound according to claim 25, wherein each strand comprises 20-22 nucleotides.

10 27. The compound according to any of the preceding claims, wherein at least one of the strands has a 3' overhang.

28. The compound according to any of the preceding claims, wherein said LNA monomer is selected from the group consisting of oxy-LNA, amino-LNA and thio-LNA.

15

29. The compound according to claim 28, wherein said LNA monomer is oxy-LNA.

30. The compound according to any of the preceding claims, wherein said LNA monomer is in the beta-D form.

20

31. A pharmaceutical composition comprising the compound as defined in any of claims 1-30 and a pharmaceutically acceptable diluent, carrier or adjuvant.

32. The pharmaceutical composition according to claim 31, wherein said composition
25 further comprises at least one active agent.

33. The pharmaceutical composition according to claim 32, wherein said active agent is a chemotherapeutic agent.

30 34. The pharmaceutical composition according to claim 33, wherein said chemotherapeutic agent is selected from the group consisting of adrenocorticosteroids, such as prednisone, dexamethasone or decadron; altretamine (hexalen, hexamethylmelamine (HMM)); amifostine (ethyol); aminoglutethimide (cytadren); amsacrine (M-AMSA); anastrozole (arimidex); androgens, such as testosterone; asparaginase (elspar); bacillus calmette-
35 gurin; bicalutamide (casodex); bleomycin (blenoxane); busulfan (myleran); carboplatin (paraplatin); carmustine (BCNU, BiCNU); chlorambucil (leukeran); chlorodeoxyadenosine (2-CDA, cladribine, leustatin); cisplatin (platinol); cytosine arabinoside (cytarabine); dacarbazine (DTIC); dactinomycin (actinomycin-D, cosmegen); daunorubicin (cerubidine); docetaxel (taxotere); doxorubicin (adriomycin); epirubicin; estramustine (emcyt);

estrogens, such as diethylstilbestrol (DES); etoposide (VP-16, VePesid, etopophos); fludarabine (fludara); flutamide (eulexin); 5-FUDR (floxuridine); 5-fluorouracil (5-FU); gemcitabine (gemzar); goserelin (zodalex); herceptin (trastuzumab); hydroxyurea (hydrea); idarubicin (idamycin); ifosfamide; IL-2 (proleukin, aldesleukin); interferon alpha
 5 (intron A, roferon A); irinotecan (camptosar); leuprolide (lupron); levamisole (ergamisole); lomustine (CCNU); mechlorathamine (mustargen, nitrogen mustard); melphalan (alkeran); mercaptopurine (purinethol, 6-MP); methotrexate (mexate); mitomycin-C (mutamucin); mitoxantrone (novantrone); octreotide (sandostatin); pentostatin (2-deoxycoformycin, nipent); plicamycin (mithramycin, mithracin); prorocarbazine (matulane); streptozocin;
 10 tamoxifen (nolvadex); taxol (paclitaxel); teniposide (vumon, VM-26); thiotepa; topotecan (hycamtin); tretinoin (vesanoid, all-trans retinoic acid); vinblastine (valban); vincristine (oncovin) and vinorelbine (navelbine).

35. The compound according to any of claims 1-30 for use as a medicament.
 15

36. Use of a compound as defined in any of claims 1-30 for the manufacture of a medicament for the treatment of cancer.

37. Use according to claim 36, wherein said cancer is in the form of a solid tumor.
 20

38. Use according to claim 36 or 37, wherein said cancer is a carcinoma.

39. Use according to claim 38, wherein said carcinoma is selected from the group consisting of malignant melanoma, basal cell carcinoma, ovarian carcinoma, breast
 25 carcinoma, non-small cell lung cancer, renal cell carcinoma, bladder carcinoma, recurrent superficial bladder cancer, stomach carcinoma, prostatic carcinoma, pancreatic carcinoma, lung carcinoma, cervical carcinoma, cervical dysplasia, laryngeal papillomatosis, colon carcinoma, colorectal carcinoma and carcinoid tumors.

30 40. Use according to claim 39, wherein said carcinoma is selected from the group consisting of malignant melanoma, non-small cell lung cancer, breast carcinoma, colon carcinoma and renal cell carcinoma.

41. Use according to claim 40, wherein said malignant melanoma is selected from the
 35 group consisting of superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma, acral melanoma, amelanotic melanoma and desmoplastic melanoma.

42. Use according to claim 36 or 37, wherein said cancer is a sarcoma.

43. Use according to claim 42, wherein said sarcoma is selected from the group consisting of osteosarcoma, Ewing's sarcoma, chondrosarcoma, malignant fibrous histiocytoma, fibrosarcoma and Kaposi's sarcoma.

5 44. Use according to claim 36 or 37, wherein said cancer is a glioma.

45. Use of a compound as defined in any of claims 1-30 for the manufacture of a medicament for the treatment of arteriosclerosis, psoriasis, diabetic retinopathy, rheumatoid arthritis, asthma, warts or allergic dermatitis.

10

46. Use of a compound as defined in any of claims 1-30 for the manufacture of a medicament for the treatment of cancer, wherein said medicament further comprises a chemotherapeutic agent selected from the group consisting of adrenocorticosteroids, such as prednisone, dexamethasone or decadron; altretamine (hexalen, hexamethylmelamine
15 (HMM)); amifostine (ethyol); aminoglutethimide (cytadren); amsacrine (M-AMSA); anastrozole (arimidex); androgens, such as testosterone; asparaginase (elspar); bacillus calmette-gurin; bicalutamide (casodex); bleomycin (blenoxane); busulfan (myleran); carboplatin (paraplatin); carmustine (BCNU, BiCNU); chlorambucil (leukeran); chlorodeoxyadenosine (2-CDA, cladribine, leustatin); cisplatin (platinol); cytosine
20 arabinoside (cytarabine); dacarbazine (DTIC); dactinomycin (actinomycin-D, cosmegen); daunorubicin (cerubidine); docetaxel (taxotere); doxorubicin (adriamycin); epirubicin; estramustine (emcyt); estrogens, such as diethylstilbestrol (DES); etoposide (VP-16, VePesid, etopophos); fludarabine (fludara); flutamide (eulexin); 5-FUDR (floxuridine); 5-fluorouracil (5-FU); gemcitabine (gemzar); goserelin (zodalex); herceptin (trastuzumab);
25 hydroxyurea (hydrea); idarubicin (idamycin); ifosfamide; IL-2 (proleukin, aldesleukin); interferon alpha (intron A, roferon A); irinotecan (camptosar); leuprolide (lupron); levamisole (ergamisole); lomustine (CCNU); mechlorethamine (mustargen, nitrogen mustard); melphalan (alkeran); mercaptopurine (purinethol, 6-MP); methotrexate (mexate); mitomycin-C (mutamucin); mitoxantrone (novantrone); octreotide
30 (sandostatin); pentostatin (2-deoxycoformycin, nipent); plicamycin (mithramycin, mithracin); prorocarbazine (matulane); streptozocin; tamoxifen (nolvadex); taxol (paclitaxel); teniposide (vumon, VM-26); thiotepa; topotecan (hycamtin); tretinoin (vesanoid, all-trans retinoic acid); vinblastine (valban); vincristine (oncovin) and vinorelbine (navelbine).

35

47. The use according to claim 46, wherein the chemotherapeutic agent is taxol (paclitaxel).

48. Use of a compound as defined in any of claims 1-30 for the manufacture of a medicament for the treatment of cancer, wherein said treatment further comprises the administration of a further chemotherapeutic agent selected from the group consisting of adrenocorticosteroids, such as prednisone, dexamethasone or decadron; altretamine
 5 (hexalen, hexamethylmelamine (HMM)); amifostine (ethyol); aminoglutethimide (cytadren); amsacrine (M-AMSA); anastrozole (arimidex); androgens, such as testosterone; asparaginase (elspar); bacillus calmette-gurin; bicalutamide (casodex); bleomycin (blenoxane); busulfan (myleran); carboplatin (paraplatin); carmustine (BCNU, BiCNU); chlorambucil (leukeran); chlorodeoxyadenosine (2-CDA, cladribine, leustatin);
 10 cisplatin (platinol); cytosine arabinoside (cytarabine); dacarbazine (DTIC); dactinomycin (actinomycin-D, cosmegen); daunorubicin (cerubidine); docetaxel (taxotere); doxorubicin (adriomycin); epirubicin; estramustine (emcyt); estrogens, such as diethylstilbestrol (DES); etoposide (VP-16, VePesid, etopophos); fludarabine (fludara); flutamide (eulexin); 5-FUDR (floxuridine); 5-fluorouracil (5-FU); gemcitabine (gemzar); goserelin (zodalex);
 15 herceptin (trastuzumab); hydroxyurea (hydrea); idarubicin (idamycin); ifosfamide; IL-2 (proleukin, aldesleukin); interferon alpha (intron A, roferon A); irinotecan (camptosar); leuprolide (lupron); levamisole (ergamisole); lomustine (CCNU); mechlorathamine (mustargen, nitrogen mustard); melphalan (alkeran); mercaptopurine (purinethol, 6-MP); methotrexate (mexate); mitomycin-C (mutamucin); mitoxantrone (novantrone);
 20 octreotide (sandostatin); pentostatin (2-deoxycoformycin, nipent); plicamycin (mithramycin, mithracin); prorocarbazine (matulane); streptozocin; tamoxifen (nolvadex); taxol (paclitaxel); teniposide (vumon, VM-26); thiotepa; topotecan (hycamtin); tretinoin (vesanoid, all-trans retinoic acid); vinblastine (valban); vincristine (oncovin) and vinorelbine (navelbine).

25

49. The use according to claim 48, wherein the chemotherapeutic agent is taxol (paclitaxel).

50. A method for treating cancer, said method comprising administering a compound as
 30 defined in any of claims 1-30 or a pharmaceutical composition as defined in any of claims 31-34 to a patient in need thereof.

51. The method according to claim 50, wherein said cancer is in the form of a solid tumor.

35 52. The method according to claim 50 or 51, wherein said cancer is a carcinoma.

53. The method according to claim 52, wherein said carcinoma is selected from the group consisting of malignant melanoma, basal cell carcinoma, ovarian carcinoma, breast carcinoma, non-small cell lung cancer, renal cell carcinoma, bladder carcinoma, recurrent

superficial bladder cancer, stomach carcinoma, prostatic carcinoma, pancreatic carcinoma, lung carcinoma, cervical carcinoma, cervical dysplasia, laryngeal papillomatosis, colon carcinoma, colorectal carcinoma and carcinoid tumors.

5 54. The method according to claim 53, wherein said carcinoma is selected from the group consisting of malignant melanoma, non-small cell lung cancer, breast carcinoma, colon carcinoma and renal cell carcinoma.

55. The method according to claim 54, wherein said malignant melanoma is selected from
10 the group consisting of superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma, acral melanoma, amelanotic melanoma and desmoplastic melanoma.

56. The method according to claim 50 or 51, wherein said cancer is a sarcoma.

15 57. The method according to claim 56, wherein said sarcoma is selected from the group consisting of osteosarcoma, Ewing's sarcoma, chondrosarcoma, malignant fibrous histiocytoma, fibrosarcoma and Kaposi's sarcoma.

58. The method according to claim 50 or 51, wherein said cancer is a glioma.
20

59. A method for treating cancer, said method comprising administering a compound as defined in any of claims 1-30 or a pharmaceutical composition as defined in any of claims 31-34 to a patient in need thereof and further comprising the administration of a further chemotherapeutic agent selected from the group consisting of adrenocorticosteroids, such
25 as prednisone, dexamethasone or decadron; altretamine (hexalen, hexamethylmelamine (HMM)); amifostine (ethyol); aminoglutethimide (cytadren); amsacrine (M-AMSA); anastrozole (arimidex); androgens, such as testosterone; asparaginase (elspar); bacillus calmette-gurin; bicalutamide (casodex); bleomycin (blenoxane); busulfan (myleran); carboplatin (paraplatin); carmustine (BCNU, BiCNU); chlorambucil (leukeran);
30 chlorodeoxyadenosine (2-CDA, cladribine, leustatin); cisplatin (platinol); cytosine arabinoside (cytarabine); dacarbazine (DTIC); dactinomycin (actinomycin-D, cosmegen); daunorubicin (cerubidine); docetaxel (taxotere); doxorubicin (adriomycin); epirubicin; estramustine (emcyt); estrogens, such as diethylstilbestrol (DES); etoposide (VP-16, VePesid, etopophos); fludarabine (fludara); flutamide (eulexin); 5-FUDR (floxuridine); 5-fluorouracil (5-FU); gemcitabine (gemzar); goserelin (zodalex); herceptin (trastuzumab); hydroxyurea (hydrea); idarubicin (idamycin); ifosfamide; IL-2 (proleukin, aldesleukin); interferon alpha (intron A, roferon A); irinotecan (camptosar); leuprolide (lupron); levamisole (ergamisole); lomustine (CCNU); mechlorethamine (mustargen, nitrogen mustard); melphalan (alkeran); mercaptopurine (purinethol, 6-MP); methotrexate

(mexate); mitomycin-C (mutamucin); mitoxantrone (novantrone); octreotide (sandostatin); pentostatin (2-deoxycoformycin, nipent); plicamycin (mithramycin, mithracin); prorocarbazine (matulane); streptozocin; tamoxifen (nolvadex); taxol (paclitaxel); teniposide (vumon, VM-26); thiotepa; topotecan (hycamtin); tretinoin
5 (vesanoid, all-trans retinoic acid); vinblastine (valban); vincristine (oncovin) and vinorelbine (navelbine).

60. The method according to claim 59, wherein the chemotherapeutic agent is taxol (paclitaxel).

10

61. Use of a compound as defined in any of claims 1-30 for the manufacture of a medicament for the treatment of Severe Acute Respiratory Syndrome (SARS).

62. A method for treating Severe Acute Respiratory Syndrome (SARS), said method
15 comprising administering a compound as defined in any of claims 1-30 or a pharmaceutical composition as defined in any of claims 31-34 to a patient in need thereof.

63. A method for producing an oligonucleotide, wherein the individual monomers are coupled using 1*H*-tetrazole or 5-ethylthio-1*H*-tetrazole.
20

64. The method according to claim 63, wherein said oligonucleotide has the structure of the sense strand or the antisense strand described in any of claims 1-30.

65. The method according to claim 63 or 64, wherein a coupling time in the range of 200-
25 1200 seconds is used.

66. The method according to claim 66, wherein said coupling time is in the range of 400-1200 seconds.

30 67. The method according to claim 66, wherein said coupling time is in the range of 600-900 seconds.

1/21




Fig. 1

2/21





Fig. 2

3/21




Fig. 3

4/21




Fig. 4

5/21




Fig. 5

6/21





Fig. 6

7/21

siRNA/siLNA targeting SARS



siRNA

	<u>Start position</u>		<u>End position</u>
siRNA SARS 1:	13,547	5'-ggaugaggaaggcaauuuatt-3' 3'-ttccuacuccuuccguaaaau-5'	13,567
siRNA SARS 2:	14,015	5'-cugguacgauuucggugautt-3' 3'-ttgaccaugcuaaagccacua-5'	14,035
siRNA SARS 3:	14,595	5'-acugucaaaacccgguaauutt-3' 3'-ttugacaguugggccauuaa-5'	14,615
siRNA SARS 4:	14,770	5'-gacaacuccuauucguagutt-3' 3'-ttcuguugaggauaagcauca-5'	14,790

siLNA

siLNA SARS 1:	13,547	5'-GgaugaggaaggcaauuuATT-3' 3'-TTccuacuccuuccguaaaaU-5'	13,567
siLNA SARS 2:	14,015	5'-CugguacgauuucggugauTT-3' 3'-TTgaccaugcuaaagccacua-5'	14,035
siLNA SARS 3:	14,595	5'-AcugucaaaacccgguaauTT-3' 3'-TTugacaguugggccauuaa-5'	14,615
siLNA SARS 4:	14,770	5'-GacaacuccuauucguaguTT-3' 3'-TTcuguugaggauaagcauca-5'	14,790

Fig. 7

8/21




Fig. 8

9/21




Fig. 9

10/21






Fig. 10

11/21

Target: *Renilla*
luciferase



Target: firefly
luciferase



■ RNA
● LNA
x mismatch

Fig. 11

12/21

LNA walk on siRNA antisense strand




Fig. 12

13/21





Fig. 13

14/21



siRNA: 5' -cuuacgcugaguacuucgatt-3'
3' -ttgaaugcgacucaugaagcu-5'

siLNA1: 5' -CuuacgcugaguacuucgaTT-3'
3' -TTgaaugcgacucaugaagcu-5'

siLNA2: 5' -CTTacgcTgagTacTTcgaTT-3'
3' -TTgaaugcgacucaugaagcu-5'

Fig. 14

15/21




Fig. 15

16/21





Fig. 16

17/21

Cloning of SARS target sequence in sense and antisense direction in firefly luciferase 3' UTR



siRNA RISC assembly and target cleavage depending on incorporated strand

siRNA maintain full effect of antisense strand while abolishing the effect of the sense strand




Fig. 17

18/21





Fig. 18

19/21




Fig. 19

20/21




Fig. 20
SUBSTITUTE SHEET (RULE 26)




Fig. 20 continued

SUBSTITUTE SHEET (RULE 26)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
30 September 2004 (30.09.2004)

PCT

(10) International Publication Number
WO 2004/083430 A3

- (51) International Patent Classification⁷: C12N 15/11, C07H 21/04, A61K 31/713, A61P 35/00
- (21) International Application Number: PCT/DK2004/000192
- (22) International Filing Date: 22 March 2004 (22.03.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
PA 2003 00442 21 March 2003 (21.03.2003) DK
60/456,888 21 March 2003 (21.03.2003) US
PA 2003 01625 31 October 2003 (31.10.2003) DK
PA 2004 00145 30 January 2004 (30.01.2004) DK
- (71) Applicant (for all designated States except US): **SANTARIS PHARMA A/S** [DK/DK]; Bøge Allé 3, DK-2970 Hørsholm (DK).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **ELMÉN, Joacim** [SE/SE]; Olof af Acrelsväg 3, 6tr, SE-171 64 Solna (SE). **WAHLESTEDT, Claes** [SE/SE]; Strandvägen 29, SE-114 56 Stockholm (SE). **LIANG, Zicai** [SE/SE]; Sevensvägen 4, SE-174 46 Sundbyberg (SE). **SØRENSEN, Anders, Malling** [DK/DK]; Gråstensgade 3, 1. tv., DK-1677 København V (DK). **ØRUM, Henrik** [DK/DK]; Vildrosevej 3, DK-3500 Værløse (DK). **KOCH, Troels** [DK/DK]; Funkiavej 47, DK-2300 Copenhagen S (DK).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report: 11 November 2004
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SHORT INTERFERING RNA (siRNA) ANALOGUES

(57) Abstract: The present invention is directed to novel double-stranded short interfering (siRNA) analogues comprising locked nucleic acid (LNA) monomers. Such compounds induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). The compounds disclosed herein has improved properties compared to non-modified siRNAs and may, accordingly, be useful as therapeutic agents, e.g., in the treatment of various cancer forms. More particularly, the present invention is directed to siRNA analogues comprising a sense strand and an antisense strand, wherein each strand comprises 12-35 nucleotides and wherein the siRNA analogues comprise at least one locked nucleic acid (LNA) monomer.

WO 2004/083430 A3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/DK2004/000192

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/11 C07H21/04 A61K31/713 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07H A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HAMADA M. ET AL.: "Effects on RNA interference in gene expression (RNAi) in cultured mammalian cells of mismatches and the introduction of chemical modifications at the 3'-ends of siRNAs" ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, MARY ANN LIEBERT, INC., vol. 12, no. 5, October 2002 (2002-10), pages 301-309, XP009006637 NEW YORK, US ISSN: 1087-2906	1-3, 6-11, 13-15, 20,25-27
Y	cited in the application the whole document ----- -/--	66

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

24 September 2004

Date of mailing of the international search report

06/10/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Macchia, G

INTERNATIONAL SEARCH REPORT

International Application No
PCT/DK2004/000192

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HAYAKAWA Y.: "Toward an ideal synthesis of oligonucleotides: development of a novel phosphoramidite method with high capability" BULLETIN OF THE CHEMICAL SOCIETY OF JAPAN, JAPAN PUBLICATIONS TRADING CO., vol. 74, no. 9, 2001, pages 1547-1565, XP001161128 TOKYO, JP ISSN: 0009-2673	63,65-67
Y	the whole document	66
A	BRAASCH D.A. ET AL.: "Novel antisense and peptide nucleic strategies for controlling gene expression" BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY, vol. 41, no. 14, 9 April 2002 (2002-04-09), pages 4503-4510, XP002975681 EASTON, PA, US ISSN: 0006-2960 the whole document	
E	WO 2004/042046 A (GRUENENTHAL GMBH (DE); SCHUBERT S; KURRECK J; GRUENWELLER A; ERDMANN V) 21 May 2004 (2004-05-21) page 46 - page 48; claims 15-27 page 31 - page 38; examples 5,6	1-12, 14-19, 25,27, 28,31, 35,36,50

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK2004/000192

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.b of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, the international search was carried out on the basis of:
- a. type of material
- ☒ a sequence listing
- ☐ table(s) related to the sequence listing
- b. format of material
- ☒ in written format
- ☒ in computer readable form
- c. time of filing/furnishing
- ☐ contained in the international application as filed
- ☐ filed together with the international application in computer readable form
- ☒ furnished subsequently to this Authority for the purpose of search
2. ☐ In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Additional comments:

INTERNATIONAL SEARCH REPORT

International application No.
PCT/DK2004/000192

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 48-60, 62 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/DK2004/000192

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2004042046 A	21-05-2004	WO 2004042046 A2	21-05-2004